Scd5p Mediates Phosphoregulation of Actin and Endocytosis by the Type 1 Phosphatase Glc7p in Yeast^D [▽]

Guisheng Zeng,* Bo Huang,* Suat Peng Neo, Junxia Wang, and Mingjie Cai

Institute of Molecular and Cell Biology, Singapore 138673, Republic of Singapore

Submitted June 26, 2007; Revised September 5, 2007; Accepted September 13, 2007 Monitoring Editor: Sandra Schmid

Pan1p plays essential roles in both actin and endocytosis in yeast. It interacts with, and regulates the function of, multiple endocytic proteins and actin assembly machinery. Phosphorylation of Pan1p by the kinase Prk1p down-regulates its activity, resulting in disassembly of the endocytic vesicle coat complex and termination of vesicle-associated actin polymerization. In this study, we focus on the mechanism that acts to release Pan1p from phosphorylation inhibition. We show that Pan1p is dephosphorylated by the phosphatase Glc7p, and the dephosphorylation is dependent on the Glc7p-targeting protein Scd5p, which itself is a phosphorylation target of Prk1p. Scd5p links Glc7p to Pan1p in two ways: directly by interacting with Pan1p and indirectly by interacting with the Pan1p-binding protein End3p. Depletion of Glc7p from the cells causes defects in cell growth, actin organization, and endocytosis, all of which can be partially suppressed by deletion of the *PRK1* gene. These results suggest that Glc7p antagonizes the activity of the Prk1p kinase in regulating the functions of Pan1p and possibly other actin- and endocytosis-related proteins.

INTRODUCTION

Clathrin-mediated endocytosis involves elaborate spatial and temporal recruitment of endocytic adaptors, coat elements, and actin cytoskeletal factors in yeast and mammalian cells (Kaksonen et al., 2003; Merrifield, 2004; Kaksonen et al., 2005, 2006). Some four protein modules have been recently suggested to be responsible for driving distinct stages of endocytosis in yeast (Kaksonen et al., 2005). The coat module consists of proteins that assemble early at the endocytic sites to initiate coat formation. The WASP/Myosin module activates the Arp2/3-mediated actin polymerization to induce membrane invagination. The actin module organizes actin filaments into a branched meshwork to facilitate coat movement, and the amphiphysin module functions in vesicle scission. The released vesicles are thought to be propelled into the cytosol by actin polymerization, accompanied by the disassembly of the coat complex (Kaksonen et al., 2006).

The essential yeast protein Pan1p plays a central role in coat formation by interacting with multiple coat proteins, including End3p, Sla1/2p, Yap1801/2p, and Ent1/2p (Tang *et al.*, 1997; Wendland and Emr, 1998; Wendland *et al.*, 1999; Tang *et al.*, 2000; Toshima *et al.*, 2007). Pan1p also possesses the ability to activate the Arp2/3 complex, and may cooperate with other nucleation-promoting factors, such as Las17p and Myo5p, to initiate actin assembly at endocytic sites (Duncan *et al.*, 2001; Sun *et al.*, 2006). Furthermore, Pan1p can directly bind to actin filaments via its WH2-like

This article was published online ahead of print in *MBC in Press* (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E07–06–0607) on September 26, 2007.

 \square \square The online version of this article contains supplemental material at *MBC Online* (http://www.molbiolcell.org).

* These authors contributed equally to this work.

Address correspondence to: Mingjie Cai (mcbcaimj@imcb.a-star. edu.sg).

region (Toshima *et al.*, 2005), thereby providing an anchor point for actin meshwork to associate with the endocytic coat. The functions of Pan1p are under a negative regulation by the serine/threonine kinase Prk1p (Zeng and Cai, 1999; Zeng *et al.*, 2001; Toshima *et al.*, 2005). Phosphorylation of Pan1p by Prk1p on the LxxQxTG motifs disrupts the Pan1p– Sla1p complex (Zeng *et al.*, 2001), and prevents Pan1p from associating with actin filaments and activating the Arp2/3 complex (Toshima *et al.*, 2005). This regulation is presumably to allow vesicles to be uncoated and uncoupled from the actin meshwork after they are internalized. Compared with the progressing studies of the regulation of Pan1p by phosphorylation, very little is known about how Pan1p regains its activity after phosphoinhibition.

The type 1 protein phosphatase (PP1) of Saccharomyces cerevisiae, Glc7p, has been shown to be involved in a diversity of cellular processes such as glycogen metabolism (Feng et al., 1991), translational control (Wek et al., 1992), glucose repression (Tu and Carlson, 1994), cell cycle progression (Hisamoto et al., 1994), and chromosome segregation (Francisco et al., 1994). The ability of Glc7p to perform such diverse functions stems presumably from its interactions with various targeting factors that direct the phosphatase to different substrates and/or sites of activity. For example, Reg1p binds and targets Glc7p to its substrates in the glucose repression regulatory pathway (Tu and Carlson, 1995). A group of Glc7p-interacting proteins have been identified by Tu et al. (1996) using the two-hybrid protein interaction assay. One of them, Scd5p, has recently been confirmed to interact with Glc7p in vivo (Chang et al., 2002). Similar to Pan1p, Scd5p is also a phosphorylation target of Prk1p, and has been shown to function in cortical actin organization and endocytosis (Henry et al., 2002; Henry et al., 2003; Huang et al., 2003). There is a pressing need, therefore, to ascertain whether Glc7p is involved in the regulation of actin and endocytosis through its interaction with Scd5p.

In this study, we demonstrate that Glc7p functions antagonistically to Prk1p in modulating the phosphorylation status of Pan1p in vivo. Scd5p is a critical factor in determining

Table 1.	Yeast	strains	used	in	this	study
----------	-------	---------	------	----	------	-------

Strain	Genotype
W303-1A	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1
W303-1B	MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1
SFY526	MATa ade2-101 trp1-901 can ^r leu2-3,112 his3-200 ura3-52 lys2-801 gal4-542 gal80-538 URA3::GAL1-lacZ
YMC422	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 pan1-4
YMC441	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 pan1::PAN1-Myc-URA3
YMC446	MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5-1 (scd5::SCD5 ^{PBM2Δ} -LEU2)
YMC448	MAT α ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5::SCD5-HA-LEU2
YMC449	MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5::SCD5 ^{AAA} -HA-LEU2
YMC471	MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5::SCD5-HA-LEU2 pan1::PAN1-Myc-URA3
YMC472	MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5-1 pan1-4 pPAN1-316
YMC473	MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5::SCD5 ^{AAA} -HA-LEU2 pan1::PAN1-Myc-URA3
YMC474	MATa ade2-1 trp1–1 can1–100 leu2–3,112 his3–11,15 ura3–1 end3∆::HIS3
YMC475	MATa ade2–1 trp1–1 can1–100 leu2–3,112 his3–11,15 ura3–1 scd5–1 end3Δ::HIS3 pEND3–316
YMC476	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 end3Δ::HIS3 scd5::SCD5-HA-LEU2
YMC477	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 prk1Δ::HIS3
YMC478	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 prk1Δ::HIS3 pan1::PAN1-Myc-URA3
YMC479	MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5-1 pan1::PAN1-Myc-UŘA3
YMC480	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 end3Δ::HIS3 pan1::PAN1-Myc-URA3
YMC481	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 glc7::GLC7-HA-LEU2
YMC482	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 pan1::PAN1-Myc-URA3 glc7::GLC7 ^{T152K} -HA-LEU2
YMC483	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 pan1::PAN1-Myc-TRP1
YMC484	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 pan1::PAN1-Myc-TRP1 glc7-td (glc7::GLC7-td-URA3)
YMC485	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 pan1::PAN1-Myc-TRP1 glc7-ntd (glc7::GLC7-ntd-URA3)
YMC486	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 prk1Δ::TRP1
YMC487	MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5Δ::HIS5 pSCD5-HA-316
YMC488	MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 prk1Δ::TRP1 scd5Δ::HIS5 pSCD5-HA-316
YMC489	MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5::SCD5 ^{PBM2Δ} -HA-LEŪ2
YMC490	MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5Δ::HIS5 pSCD5-HA-316 glc7::GLC7 ^{T152K} -Myc-LEU2
YMC491	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5::SCD5-Myc-TRP1
YMC492	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5::SCD5-Myc-TRP1 glc7-ntd (glc7::GLC7-ntd-URA3)
YMC493	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5::SCD5-Myc-TRP1 glc7-td (glc7::GLC7-td-URA3)
YMC494	MATa trp1-1 leu2-3,112 his3 ura3 pan1::PAN1-GFP-HIS3MX
YMC495	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 prk1::PRK1-GFP-LEU2
YMC496	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5::SCD5-GFP-HIS3MX
YMC497	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 pan1::PAN1-CFP-TRP1 prk1::PRK1-GFP-LEU2
YMC498	MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 pan1::PAN1-CFP-TRP1 scd5::SCD5-GFP-HIS3MX
YMC499	MAT α ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 glc7-ntd (glc7::GLC7-ntd-URA3)
YMC500	MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 glc7-td (glc7::GLC7-td-URA3)
YMC501	MATα ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 prk1Δ::HĪIS3 glc7-td (glc7::GLC7-td-URA3)
YMC502	MAT α ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1 scd5::SCD5 ^{AAA} -HA-LEU2 pan1::PAN1-GFP-HIS3MX

the phosphorylation status of Pan1p, as it serves not only as a Glc7p targeting factor but also as a switch in phosphorylation of Pan1p. These findings provide new insight into the mechanism that operates in the cycle of phosphoregulation of actin-driven endocytosis in yeast.

MATERIALS AND METHODS

Strains, Plasmids, and General Methods

Yeast strains and plasmids used in this study are listed in Table 1 and 2, respectively. Yeast cells were grown in standard yeast extract-peptone-dextrose (YEPD) or synthetic complete (SC) medium lacking appropriate amino acids for plasmid maintenance. In experiments requiring the expression of genes under the GAL1 promoter, raffinose instead of dextrose was used as the carbon source and galactose was later added for GAL1 induction. To maintain the growth of glc7-td, glc7-ntd, and $prk1\Delta$ glc7-td mutants, CuSO₄ was added to the medium at a final concentration of 0.1 mM. Mutations on Scd5p (PBM2A, AAA, and EEE) and Glc7p (T152K and ntd) were generated by polymerase chain reaction (PCR) mutagenesis. Strains YMC422, YMC441, YMC446, YMC448, and YMC449 were generated as described previously (Zeng and Cai, 1999; Zeng et al., 2001; Huang et al., 2003). Gene deletions in YMC474, YMC477, YMC486, and YMC487 were created by integrating a HIS3, TRP1, or Schizosaccharomyces pombe HIS5 selection cassette to replace the chromosomal loci. Crosses of YMC446 with YMC422 containing pPAN1-316, YMC446 with YMC474 containing pEND3-316, YMC486 with YMC487, and DDY3063 (Kaksonen et al., 2005) with W303-1A, followed by sporulation and dissection, produced YMC472, YMC475, YMC488, and YMC494, respectively.

The C-terminal green fluorescent protein (GFP)-fused *SCD5* in YMC496 and YMC498 were generated by the PCR-targeting method as described previously (Wach *et al.*, 1997). Other strains were generated by integrating various linearized plasmids into corresponding host cells, respectively. Bacterial strains DH5 α and BL21 were grown on standard medium supplemented with 100 μ g/ml ampicillin to maintain plasmids. Genetic and recombinant DNA manipulations were performed according to standard techniques.

Protein Extraction, Immunoprecipitation, and Immunoblotting

Yeast extracts were prepared by either glass beads method or trichloroacetic acid (TCA) precipitation method as described previously (Tang et al., 1997; Huang et al., 2003). Immunoprecipitation and immunoblotting followed the published procedure (Tang et al., 1997) with slight modifications. The beadsconjugated anti-hemagglutinin (HA) or anti-Myc polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were used to immunoprecipitate epitope-tagged proteins. For immunoblotting of precipitated proteins, monoclonal anti-HA or anti-Myc (clone 12CA5 and 9E10, respectively; Roche Applied Science, Indianapolis, IN), rabbit anti-phosphothreonine (anti-PThr; Zymed Laboratories, San Francisco, CA), or rabbit anti-G6PDH (Sigma-Aldrich, St. Louis, MO) antibodies were used as required. Horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit antibodies (GE Healthcare, Chalfont St. Giles, United Kingdom) were used together with the ECL system (GE Healthcare) to visualize the antibody-antigen complex. Treatment of immunoprecipitates with calf intestinal alkaline phosphatase (CIP) was performed as described previously (Zeng and Cai, 1999). To increase the basal level of in vivo phosphorylated Scd5p, cells with locus-expressed Scd5-HA were incubated with the phosphatase inhibitor cocktail (10 µM sodium fluTable 2. Plasmid constructs used in this study

 DNA fragment encoding SciD (1584 amino acide jan) was cleaned into pCBK17 SCDS-CB DNA fragment encoding SciD (1397 an) was cloned into pCBK17 SCDS-NJ-BD DNA fragment encoding SciD (1397 an) was cloned into pCBK17 SPCDS-NJ-BD DNA fragment encoding Pan10 (149-130) was cloned into pCAD17 PPANI-READ DNA fragment encoding Pan10 (129-1480 an) was cloned into pCAD17 PPANI-BC-CD DNA fragment encoding Pan10 (129-1480 an) was cloned into pCAD17 PPANI-SIA TDF PANI SPC CGT LLZ, DNA fragment encoding Pan10 (129-1480 an) was cloned into pCAD17 PPANI-SIA TDF PANI SPC CGT LLZ, DNA fragment encoding Pan10 (129-1480 an) was cloned into pCAD17 PPANI-SIA TDF PANI SPC CGT LLZ, DNA fragment encoding PCM (129-1480 an) was cloned into pCI-SIAT PPANI-SIA TDF PANI SPC CGT LLZ, DNA fragment encoding PCM (129-1480 an) was cloned into pCI-SIAT PPANI-SIA TDF PANI SPC CGT LLZ, DNA fragment encoding PCM (129-1480 an) was cloned into pCI-SIAT PPANI-SIA TDF PANI SPC TDF PANI SPC	Construct	Description
SECDS C ED DNA fragment encoding Scdp (103 872 a) was cloned into pCBK17 SECDS N. ED DNA fragment encoding Scdp (102 341 a) was cloned into pCBK17 SECDS N. ED DNA fragment encoding Scdp (102 341 a) was cloned into pCABT7 PANI LELAD DNA fragment encoding Pan1p (103 841 a) was cloned into pCADT7 PANI CC AD DNA fragment encoding Pan1p (123 +1110 a) was cloned into pCADT7 PANI AT The FANI gene was generated by PCR and cloned into pCSB16 (Tang et al., 2000) PCANI AT The FANI gene was generated by PCR and cloned into pCSB16 (Tang et al., 2000) PCANI AT The FANI gene was generated by PCR and cloned into pCSB16 (Tang et al., 2000) PCANI AT The FANI gene was generated by PCR and cloned into pCSB16 (Tang et al., 2000) PCEX DNI His SCDS C: DNA fragment encoding SCDS (705 327 a) was cloned into pFS12 a) PETSCDS AT His SCDS C: DNA fragment encoding SCDS (705 327 a) was cloned into pFS13 (Tang et al., 1997) PENJ33-61 The FAJ3 gene was generated by PCR and cloned into pCS17 (Tang et al., 1997) PENJ35-71 The SAD3 gene was generated by PCR and cloned into pCS17 (Tang et al., 1997) PENJ35-81D DNA fragment encoding SCDS (745 22 a) was cloned into pCS17 (Tang et al., 1997) PENJ35-81D DNA fragment encoding SCDS (745 22 a) was cloned into pCS17 (Tang et al., 1997) </td <td>pSCD5-N-BD</td> <td>DNA fragment encoding Scd5p (1-534 amino acids [aa]) was cloned into pGBKT7</td>	pSCD5-N-BD	DNA fragment encoding Scd5p (1-534 amino acids [aa]) was cloned into pGBKT7
 pictO5-NLBD DNA fragment encoding SciDs (2023) and was cloned into pCBRT7 pictO5-NLBD DNA fragment encoding Paph (2457) (2023) and was cloned into pCADT7 pictO5-NLBD DNA fragment encoding Paph (2457) (2023) and cloned into pCADT7 pictO5-NLBD DNA fragment encoding Paph (2457) (2430) was cloned into pCADT7 pictO5-NLBD DNA fragment encoding Paph (2457) (2400) was cloned into pCADT7 pictO5-NLBD DNA fragment encoding Paph (2457) (2400) was cloned into pCADT7 pictO5-NLBD DNA fragment encoding Paph (2457) (2400) was cloned into pCF316 (2007) (2000) pictO5-NLBD DNA fragment encoding C3DF (1203) and was cloned into pCF314 (2000) pictO5-NLBD DHA fragment encoding C3DF (1203) and was cloned into pF1-32a pictO5-NLBD DHA fragment encoding SciDF (12052) and was cloned into pF1-32a pictO5-NLBD DHA fragment encoding SciDF (12052) and was cloned into pF334 (2000) (2000) pictO5-NLBD DNA fragment encoding SciDF (12052) and was cloned into pF334 (2000) (2000) pictO5-NLDD DNA fragment encoding SciDF (12052) and was cloned into pF334 (2000) (2000) pictO5-NLDD DNA fragment encoding SciDF (135372 and was cloned in frame with a C-terminal <i>IAc</i> epitope followed by the <i>ADD11</i> terminitary in pS530 (1100) (2007) pictO5-NLD DNA fragment encoding SciDF (135372 and was cloned in frame with a N-terminal <i>Myc</i> epitope and placed under is own promoter control in pS5314 pictO5-NLD DNA fragment encoding SciDF (135472 and was cloned in frame with a N-terminal <i>Myc</i> epitope and placed under is own promoter control in pS5314 pictO5-NLD DNA fragment encoding Paph (1203-149a) was cloned in frame with a N-terminal <i>My</i>	pSCD5-C-BD	DNA fragment encoding Scd5p (535-872 aa) was cloned into pGBKT7
 pPCD5-RV28D DNA fragment encoding Sed5(502-534 a) was cloned into pCADT7 pPANI-R2-AD DNA fragment encoding Parls (1-638-510 aa) was cloned into pCADT7 pPANI-R2-AD DNA fragment encoding Parls (1-631 bio a) was cloned into pCADT7 pPANI-R2-AD DNA fragment encoding Parls (1-631 bio a) was cloned into pCADT7 pPANI-R2-AD DNA fragment encoding Parls (1-631 bio a) was cloned into pCADT7 pPANI-S11 The PANI gene was generated by PCR and cloned into pES310 frag et al., 2000) pCEX-L82 DNA fragment encoding CSD5 (1-632 A) was cloned into pET-32a pET-SCD5-N1 His-SCD5-K2. DNA fragment encoding CSD5 (1-632 A) and was cloned into pET-32a pET-SCD5-N1 His-SCD5-K2. DNA fragment encoding CSD5 (1-632 A) was cloned into pET-32a pET-SCD5-R1 PENJ3-311 The FNJ3 gene was generated by PCR and cloned into pCBNT7 pENJ3-311 The FNJ3 gene was generated by PCR and cloned into pCBNT7 pENJ3-311 The FNJ3 gene was generated by PCR and cloned into pCBNT7 pENJ3-810 DNA fragment encoding Scd5 (1-534 a) was cloned into pCBNT7 pENJ3-840 DNA fragment encoding Scd5 (1-534 a) was cloned into pCBNT7 pENJ3-840 DNA fragment encoding Scd5 (1-534 a) was cloned into pCANT7 pENJ3-841 pENJ3-841 DNA fragment encoding Scd5 (1-534 a) was cloned into pCANT7 pENJ3-841 pENJ3-841 pPANI-841 pPANI-842 pPANI-843 pPANI-843 pPANI-843 pPANI-844 pPANI-843 pPANI-843 pPANI-843 pPANI-844 pPANI-844 pPANI-8444 pPANI-8444 pPANI-8444 <l< td=""><td>pSCD5-N1-BD</td><td>DNA fragment encoding Scd5p (1-301 aa) was cloned into pGBKT7</td></l<>	pSCD5-N1-BD	DNA fragment encoding Scd5p (1-301 aa) was cloned into pGBKT7
 PÅNH-LRFAD DNA fragment encoding Pan1p (1487-13a) was cloned into pGAD17 PÅNH-LRFAD DNA fragment encoding Pan1p (1487-13a) was cloned into pGAD17 PÅNH-LRFAD DNA fragment encoding Pan1p (1487-13a) was cloned into pGAD17 PÅNH-SLA The PANI Space was generated by PCR and cloned into pRS11 (Tang et al., 200) PÉXH-LSL (STF-LREZ) DNA fragment encoding Pan1p (1547-13a) was cloned into pFC314. CGT-LRZ (DNA fragment encoding PLOP (1547)-134 was cloned into pFC314. PTSCD5-N2 His-SCD5-N1 His-SCD5-N2. DNA fragment encoding Pan1p (1547)-134 was cloned into pFC32a. PEXHSL334 The EAD3 gene was generated by PCR and cloned into pRS314 (Tang et al., 2007) PEND3-316 The EAD3 gene was generated by PCR and cloned into pRS314 (Tang et al., 1997) PSCD5-LN-205 PEND3-316 The EAD3 gene was generated by PCR and cloned into pGBNT7 PSCD5-LN-205 DNA fragment encoding EaD3 (1-249 al.) was cloned into pGBNT7 PSCD5-CAD DNA fragment encoding EaD3 (1-249 al.) was cloned into pGBNT7 PSCD5-CAD DNA fragment encoding EaD3 (1-249 al.) was cloned into pGBNT7 PSCD5-CAD DNA fragment encoding EaD3 (1-239 al.) was cloned into pGBNT7 PSCD5-CAD DNA fragment encoding Scd5 (1-238 al.) was cloned into pGBNT7 PSCD5-CAD DNA fragment encoding Pan1p (1252-1480 al.) was cloned in frame with an N-terminal Myc epitope and placed under is own promoter control in pRS314 PANI-CMPC304 DNA fragment encoding Pan1p (1252-1480 al.) was cloned in frame with an N-terminal Myc epitope followed by the AD71 terminator in pRS304 (Cang et al. 2001) PANI-MAC934 DNA fragment encoding PA10 (1-218 al.) was cloned in frame with	pSCD5-N2-BD	DNA fragment encoding Scd5p (302-534 aa) was cloned into pGBKT7
 PTANI, L22-AD DNA fragment encoding Tanje (43-713 a) was cloned into pCADT7 PTANI, CC, AD DNA fragment encoding Tanje (41-1310 a) was cloned into pCADT7 PTANI, STAD DNA fragment encoding Tanje (41-1310 a) was cloned into pCADT7 PTANI, SIA THE, PTANI, Zer, Was generated by PCR and cloned into pFS316 (Trange <i>d.</i>, 2000) PCASI, R2 CST-14, R2, DNA fragment encoding SCDP (153-72 a) was cloned into pFT-32a PTT-SCD5-N1 His-SCD5-N2, DNA fragment encoding SCDP (153-72 a) was cloned into pFT-32a PTT-SCD5-N1 His-SCD5-N2, DNA fragment encoding SCDP (153-72 a) was cloned into pFT-32a PSCD5-H3, The FNDS gene was generated by PCR and cloned into pRS161 PSCD5-H3, The gene was generated by PCR and cloned into pRS17 PSCD5-H3, The gene was generated by PCR and cloned into pCRS17 PSCD5-H3, The gene was generated by PCR and cloned into pCRS17 PSCD5-H3, The gene was generated by PCR and cloned into pCADT7 PSCD5-H3, The gene was generated by PCR and cloned into pCRS17 PSCD5-H3, The generat encoding SCD5 (153-872 a) was cloned into pCADT7 PSCD5-AD DNA fragment encoding SCD5 (153-872 a) was cloned into pCADT7 PSCD5-AD DNA fragment encoding SCD5 (153-814) and scheme with an N-terminal Myc epitope and placed under its own promoter control in pRS314 PMyc-END3A-314 DNA fragment encoding Tab) (1-23 a) was cloned in frame with an N-terminal Myc epitope followed under its own promoter control in pRS314 PANIC-MYc-304 DNA fragment encoding Tab) (1-23 a) was cloned in frame with a C-terminal Myc epitope followed under its own promoter control in pRS314 PANIC-MYc-305 PANIC-MYc-305 PANIC-MYC-304 DNA fragment encoding Tab) (1-2	pPAN1-LR1-AD	DNA fragment encoding Pan1p (1-385 aa) was cloned into pGADT7
 PIANI, TY, DD DNA fragment encoding Tarip (1241-310 a) was cloned into pLAD17 DNA fragment encoding Tarip (1241-880 a) was cloned into pCAD7 PIANI, TY, DD DNA fragment encoding Tarip (1241-880 a) was cloned into pCAD7 PIANI, TY, DD PIANI, TY, DD, TY, TY, DD, TY, TY, DD, TY, TY, DD, TY, DD	pPAN1-LR2-AD	DNA fragment encoding Pan1p (384-713 aa) was cloned into pGADT7
 DAN Tragment encoding Tanip (L2C 1400 a) was cloned into pCAD17 PANL316 The PANT gene was generated by PCR and cloned into pET316. Tens of al. 2000) pCEX-LR2 (DS-N1 His-SCD-N1, Z) DNA tragment encoding SCD5 (135-872 a) was cloned into pET-32a pET-SCD5-N2 His-SCD-SC, DNA tragment encoding SCD5 (135-872 a) was cloned into pET-32a pET-SCD5-N2 His-SCD-SC, DNA tragment encoding SCD5 (135-872 a) was cloned into pET-32a pET-SCD5-N2 His-SCD-SC, DNA tragment encoding SCD5 (135-872 a) was cloned into pET-32a pETN33-316 The END3 gene was generated by PCR and cloned into pES314 (Tang <i>et al.</i>, 1997) pSCD5-HA-305 UNA tragment encoding SCD5 (135-872 a) was cloned into pCHT7 pSCD5-HA-305 UNA tragment encoding SCD5 (135-872 a) was cloned into pCHT7 pSCD5-CAD DNA tragment encoding SCD5 (135-872 a) was cloned into pCAD17 pSCD5-CAD DNA tragment encoding SCD5 (135-872 a) was cloned into pCAD17 pSCD5-CAD DNA tragment encoding SCD5 (135-872 a) was cloned into the ACNT7 pSCD5-CAD DNA tragment encoding SCD5 (135-872 a) was cloned in trame with an N-terminal Myc epitope and placed under is own promoter control in pES314 pMyc-END3-314 DNA tragment encoding SCD5 (13-572 a) ay was cloned in trame with an N-terminal Myc epitope and placed under is own promoter control in pES314 pMyc-END3-314 DNA tragment encoding SCD5 (13-572 a) ay was cloned in trame with an N-terminal Myc epitope and placed under is own promoter control in pES314 pMyc-END3-314 DNA tragment encoding SCD5 (13-572 a) ay was cloned in trame with an N-terminal Myc epitope and placed under is own promoter control in pES314 pMA tragment encoding SCD5 (12-573 a) was cloned in trame with a N-terminal Myc epitope followed by the ADPH terminator in pES304 (22-36) a) was cloned in trame with a C-terminal Myc epitope followed by the ADPH terminator in pES314	pPAN1-CC-AD	DNA fragment encoding Pan1p (641-1310 aa) was cloned into pGAD17
 pTANI-316 The PANT gene was generated by PCR and cloned into pES316 (Tang et al. 2000) pCEX-1R2 CONF TARGENET CONFIGURATION (STATE) pETSCD5-V1 LESCD5-V1, DNA fragment encoding SCD5 (0253-872 aa) was cloned into pET-32a pETSCD5-V2 LESCD5-V2, DNA fragment encoding SCD5 (0253-872 aa) was cloned into pET-32a pETSCD5-V3 LESCD5-V2, DNA fragment encoding SCD5 (0253-872 aa) was cloned into pET-32a pETSCD5-V3 LESCD5-V2, DNA fragment encoding SCD5 (025-872 aa) was cloned into pET-32a pETSCD5-V4 DESCD5-V4 DESCD5-V5 DESCD5-	pPANI-PP-AD pPANI-314	DNA tragment encoding Panip (1239-1480 aa) was cloned into pGAD1/
 EVEX.LR2 (ST-LR2: DNA inagment encoding Fanlp (38+715 aa) was cloned into pET-32a PET-SCD5-N1 His-SCD5-N1, DNA inagment encoding ScD5p (302-334 aa) was cloned into pET-32a PET-SCD5-C His-SCD5-C, NJ, BAA, Fagment encoding SCD5p (302-334 aa) was cloned into pET-32a PEND3-316 The END3 gene was generated by PCR and cloned into pES314 (Tang <i>et al.</i>, 1997) PEND3-316 The END3 gene was generated by PCR and cloned into pES314 (Tang <i>et al.</i>, 1997) PEND3-316 The END3 gene was generated by PCR and cloned into pES314 (Tang <i>et al.</i>, 1997) PEND3-BD the ADHI terminator in PES306 (Tang <i>et al.</i>, 2000) PEND3-BD DNA fragment encoding ScD5p (153-872 aa) was cloned into DGRKT7 PEND3-BD DNA fragment encoding End5p (12-349 aa) was cloned into pCADT7 PSCD5-C-AD DNA fragment encoding End5p (12-33 aa) was cloned in frame with an N-terminal M₂ epitope and placed under its own promoter control in pES314 PMV-END3-314 DNA fragment encoding End5p (12-33 aa) was cloned in frame with an N-terminal M₂ epitope and placed under its own promoter control in pES314 PMV-END3A-314 DNA fragment encoding End5p (12-33 aa) was cloned in frame with an N-terminal M₂ epitope and placed under its own promoter control in pES314 PMV-END3A-314 DNA fragment encoding End5p (12-33 aa) was cloned in frame with an N-terminal M₂ epitope followed by the <i>ADPHI</i> terminator in pES366 (Cang and Ca. 1999) PGALHA-PRK1-305 PGALHA-PRK1-316 PGALHA-PRK1-316	pPAN1-316	The PAN1 gene was generated by PCR and cloned into pRS316 (Tang et al. 2000)
pTTSCD5-N1 His-SCD5-N1; DNÅ fragment encoding SCD5 (202-S4a a) was cloned into pTT-32a pTTSCD5-N2 His-SCD5-C; DNA fragment encoding SCD5 (202-S4a a) was cloned into pTT-32a pETSCD5-N3 His-SCD5-C; DNA fragment encoding SCD5 (202-S4a a) was cloned into pTS314 pEND3-316 The END3 gene was generated by PCR and cloned in tarme with a C-terminal HA epitope followed by the ADH terminator in pRS405 (Huang et al., 2003) pEND3-HD DNA fragment encoding Scd5 (1-534 a) was cloned into pCBK17 pSCD5-N-AD DNA fragment encoding Scd5 (1-534 a) was cloned into pCBK17 pSCD5-N-AD DNA fragment encoding Scd5 (1-534 a) was cloned into pCAD17 pSCD5-C-D DNA fragment encoding Scd5 (1-534 a) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS314 pMycEND3-314 DNA fragment encoding End5 (1-235 aa) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS314 pNA fragment encoding PAD5 (1-1634 a) was cloned in frame with a C-terminal Myc epitope and placed under is own promoter control in pRS314 pANA fragment encoding PLAD5 (1-1634 a) was cloned in frame with a C-terminal Myc epitope followed by the ADH terminator in pRS316 (Zeng and Cai, 1999) pGL2-LHA.PRK1316 DNA fragment encoding PLAD5 (1-1634 a) was cloned in frame with a C-terminal Myc epitope followed by the ADH terminator in pRS316 (Zeng and Cai, 1999) pGL2-Fr-HA-305 T	pGEX-LR2	GST-LR2; DNA fragment encoding Pan1p (384-713 aa) was cloned into pGEX-4T-1
pTT-SCD5-N2 His-SCD5-N2; DNA fragment encoding SCD5 (535-872 an) was cloned into pTT-32a pFND3-316 The FND3 gene was generated by PCR and cloned into pR5314 (Tang et al., 1997) pSND3-314 The FND3 gene was generated by PCR and cloned into pCBK17 pSND3-314 The FND3 gene was generated by PCR and cloned into pCBK17 pSND3-ED DNA fragment encoding fnd5; (C1-349 aa) was cloned into pCBK17 pSND3-ED DNA fragment encoding fnd5; (C1-349 aa) was cloned into pCBK17 pSND3-ED DNA fragment encoding fnd5; (C1-349 aa) was cloned in for pCBK17 pMO-END3-A14 DNA fragment encoding fnd5; (C1-349 aa) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pR5314 pMy-END3A-314 DNA fragment encoding fnd5; (C1-253 aa) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pR5314 pMy-END3A-314 DNA fragment encoding fnd5; (C1E-349 aa) was cloned in frame with a N-terminal Myc epitope and placed under its own promoter control in pR5314 pFND3A-314 DNA fragment encoding fnd5; (C1E-349 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pR536 (Zeng et al., 2001) pEND3A-314 DNA fragment encoding fnd5; (C1E-349 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pR536 (Zeng et al., 2001) pEND3A-314 DNA fragment encoding fnd5; (C1E	pET-SCD5-N1	His-SCD5-N1; DNA fragment encoding Scd5p (1-301 aa) was cloned into pET-32a
pETSOB-C His-SCD5-C; DNA fragment encoding SCD7 (DS7-872 a) was cloned in the PE331 pEND3-316 The END3 gene was generated by PCR and cloned in the pES314 (Tang <i>et al.</i> , 1997) pEND3-314 The END3 gene was generated by PCR and cloned in frame with a C-terminal HA epitope followed by the ADH terminator in pRS95 (Huang <i>et al.</i> , 2003) pEND3-BD DNA fragment encoding Scd7 (PS42 a) was cloned in the pCRS17 pSCD5-CAD DNA fragment encoding Scd7 (1-349 a) was cloned in the pCADT7 pSCD5-CAD DNA fragment encoding Scd7 (1-349 a) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS34 pMy-END3-314 DNA fragment encoding Scd7 (1-349 a) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS34 pMy-END3-A:314 DNA fragment encoding End39 (1-233 a) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS314 pANic Myc-304 DNA fragment encoding Prath (1252-1480 a) was cloned in frame with a C-terminal Myc epitope followed by the ADH terminator in pRS316 (Zeng and Cai, 1999) pCAL-HA-PRK1-315 DNA fragment encoding Prath (1252-1480 a) was cloned in frame with a C-terminal Myc epitope followed DNA fragment encoding Prath (18-30 a) and sole one in frame with a C-terminal Myc epitope followed by the ADH terminator in pRS314 (DNA fragment encoding Prath (18-30 a) and sole one in frame with a C-terminal Myc epitope followed DNA fragment encoding PrAth (1252 a) and was cloned in frame with a C-terminal M	pET-SCD5-N2	His-SCD5-N2; DNA fragment encoding SCD5p (302-534 aa) was cloned into pET-32a
 pEND3-316 The EAD3 gene was generated by PCR and cloned into pESS16 pEND3-314 The EAD3 gene was generated by PCR and cloned into pCBS16 pEND3-BD DNA fragment encoding GGG (Huang <i>et al.</i>, 2003) pEND3-BD DNA fragment encoding GGG (Huang <i>et al.</i>, 2003) pEND3-BD DNA fragment encoding GGG (Huang <i>et al.</i>, 2003) pEND3-BD DNA fragment encoding GGG (Huang <i>et al.</i>, 2003) pEND3-BD DNA fragment encoding GGG (Hang <i>et al.</i>, 2003) pEND3-CAD DNA fragment encoding GGG (Hang <i>et al.</i>, 2003) pMy-END3-314 DNA fragment encoding GGG (H-394 a) was cloned in the pGAD17 pSCD5-CAD DNA fragment encoding GGG (H-394 a) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS314 DNA fragment encoding End3 (H-394 a) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS314 pPANIE-My-306 DNA fragment encoding End3 (H-252 + 480 a) was cloned in frame with a N-terminal Myc epitope followed by the ADH1 terminator in pRS304 (H252 + 480 a) was cloned in frame with a N-terminal Myc epitope followed by the ADH1 terminator in pRS304 (H34) a) was cloned in frame with the HA epitope and placed under its own promoter control in pRS314 pCAL-HA-PRK1-316 DNA fragment encoding End5 (H252 + 340 a) as placed under its own promoter control in pRS314 pCAL-HA-PRK1-316 DNA fragment encoding PhiLp (H34) aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304 (H34) aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304 pCLC7-104-305 pCAL-HA-PRK1-316 DNA fragment encoding PhiLp (H34) aa) was cloned in frame with	pET-SCD5-C	His-SCD5-C; DNA fragment encoding SCD5p (535-872 aa) was cloned into pET-32a
 PEND3-314 Die E/D3 gene was generated by PCK and cloned in forme with a C-terminal HA epitope followed by the //DH1 terminator in pR5305 (Huang <i>et al.</i>, 2003) PEND3-BD DNA fragment encoding End5p (7:34% a) was cloned in the JCBKT7 PEND3-BD DNA fragment encoding End5p (7:34% a) was cloned in the JCBKT7 PMy-END3-314 DNA fragment encoding End5p (7:34% a) was cloned in the JCATT7 PMy-END3-314 DNA fragment encoding End5p (7:34% a) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pR5314 PMy-END3AC-314 DNA fragment encoding End5p (1:34% a) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pR5314 PAN-FRIDEN-314 DNA fragment encoding End5p (1:34% a) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pR5316 (2eng at 0., 2011) PEND3AC-314 DNA fragment encoding End5p (1:634 a) was placed under its own promoter control in pR5314 DNA fragment encoding End5p (1:634 a) was placed under its own promoter control in pR5314 DNA fragment encoding End5p (1:634 a) was cloned in frame with the HA epitope and placed under its own promoter control in pR5314 DNA fragment encoding PR1p (1:810 a) was cloned in frame with the HA epitope and placed under its own promoter control in pR5314 DNA fragment encoding PR1p (1:810 a) was cloned in frame with the HA epitope and placed under its own promoter control in pR5314 DNA fragment encoding PR1p (0:431 a) was cloned in frame with the HA epitope and placed under GAL1 promoter control in pR5314 (2mg and Cai, 1999) pGLC7-n14-305 pGLC7-n14-305 pGLC7-n14-305 pCLC7-n14-305 pCLC7-n14-305 pCLC7-n14-305 pCLC7-n14-305	pEND3-316	The END3 gene was generated by PCR and cloned into pRS316
 DNA fragment encoding Subp (7-8-2 al) was cloned in frame with a C-terminal <i>H</i>/<i>x</i> epitope followed by the <i>ADPH</i> terminator in pRSS16 (Huang <i>et al.</i>, 2003) PENDA-BD DNA fragment encoding EndSp (1-84 a) was cloned into pCBKT7 PSDS-CAD DNA fragment encoding Scd5p (1-349 a) was cloned into pCBKT7 PSOS-CAD DNA fragment encoding Scd5p (1-349 a) was cloned into pCBKT7 PMV-END3.14 DNA fragment encoding Scd5p (1-349 a) was cloned into pCMT7 PMV-END3.2C-314 DNA fragment encoding Scd5p (1-253 a) was cloned in frame with an N-terminal <i>Myc</i> epitope and placed under its own promoter control in pRS314 (1-253 a) was cloned in frame with an N-terminal <i>Myc</i> epitope and placed under its own promoter control in pRS314 (1-253 a) was placed under its own promoter control in pRS314 PNA fragment encoding EndSp (116-349 a) was placed under its own promoter control in pRS314 (1-253 a) was placed under its own promoter control in pRS314 (1-253 a) was blaced under its own promoter control in pRS314 PCAL-HA-PRK131 DNA fragment encoding EndSp (116-349 a) was placed under its own promoter control in pRS314 (2-2013) and was cloned in frame with the <i>HA</i> epitope and placed under its own promoter control in pRS314 (2-2013) and was cloned in frame with the <i>HA</i> epitope and placed under its own promoter control in pRS314 (2-2013) and was cloned in frame with the <i>HA</i> epitope and placed under <i>GAL1</i> promoter control in pRS316 (2-2014) and was cloned in frame with a C-terminal <i>Myc</i> epitope followed by the <i>ADPH</i> terminator in pRS306 (2-2014) and was cloned in frame with a C-terminal <i>Myc</i> epitope followed by the <i>ADPH</i> terminator in pRS306 (2-2014) promoter control in pRS314 (2-2013) promoter ontrol in pRS306 (2-2014) promoter ontrol in pRS306 (2-2014) promoter control in pRS306 (2-2014) promoter control in pRS306 (2-2014) promoter control in pRS306 (2-2014) prom	pEND3-314	The ENDS gene was generated by PCR and cloned into pRS314 (Tang <i>et al.</i> , 1997).
pENDar-BD The PLAPT Infinitiation in proceeding et al., 2003 pENDar-BD DNA fragment encoding Ends (1-14349a) was cloned into pC6RT7 pSCD5-N-AD DNA fragment encoding Ends (53-572 al.) was cloned into pCADI7 pSCD5-C-AD DNA fragment encoding Ends (53-572 al.) was cloned into pCADI7 pMyc-END3-314 DNA fragment encoding Ends (53-572 al.) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pSS314 pMyc-END3-314 DNA fragment encoding EndS (1-14349 a) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pSS314 pMyc-END3A-314 DNA fragment encoding EndS (116-349 a) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pSS316 (2cng at 0, 201) pEND3A-314 DNA fragment encoding EndS (116-349 a) was placed under its own promoter control in pSS314 pCGL-1HA-PRK1-316 DNA fragment encoding EndS (16-349 a) was placed under its own promoter control in pSS314 pGA1-HA-PRK1-316 DNA fragment encoding FadB (16-349 a) was cloned in frame with the HA epitope and placed under its own promoter control in pSS314 pGLC7-1HA-PRK1-316 DNA fragment encoding FadB (16-349 a) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pSS314 (211) pGLC7-1HA-PRK1-316 DNA fragment encoding FadB (16-349 a) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pSS305 (201)<	pSCD5c-HA-305	DNA tragment encoding Scop ($79-8/2$ a) was cloned in frame with a C-terminal HA epitope followed by the ADUI terminator in π pS205 (Hunga et al. 2002)
PENDS-BD DNA fragment encoding End3p (72:49 a) was cloned into pCADIT PSCD5-N-D DNA fragment encoding Scd0p (1354 a) was cloned into pCADIT PSCD5-N-D DNA fragment encoding Scd0p (1354 a) was cloned into pCADIT PMyc-END3-14 DNA fragment encoding Scd0p (1354 a) was cloned in to pCADIT PMyc-END3AC-314 DNA fragment encoding End3p (1-394 a) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS314 PMyc-END3AN-314 DNA fragment encoding End3p (1-534 a) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS314 PNA1c-Myc-306 DNA fragment encoding End3p (16-349 a) was cloned in frame with a C-terminal Myc epitope followed by the <i>ADH1</i> terminator in pRS316 (Zeng at al., 2001) PGAL-HA-PRK11 DNA fragment encoding End3p (16-349 a) was cloned in frame with He HA epitope followed by the <i>ADH1</i> terminator in pRS316 (Zeng and Cai, 1999) PGCX-111 DNA fragment encoding PA1P (1-810 a) was cloned in the BA offer the HA epitope and placed under CAL1 promoter control in pRS316 (Zeng and Cai, 1999) PGCX-111 CFT_HA, TRAGN TARMENT (Zeng and Cai, 1999) PGCX-112 DNA fragment encoding PA1P (9-833 a) was cloned in frame with a C-terminal Myc epitope followed by the <i>ADH1</i> terminator in pRS305 PGLC7n-14-305 Ti32K mutation was introduced into PGCVFHA was cloned in tor pGS147 PGCVFHA was cloned in frame with a C-terminal Myc ep	nFND3n-BD	DNA fragment encoding End30 (1-141 a) was cloned into pCBKT7
pSCD5:N-AD DNA fragment encoding Scd5p (1-534 aa) was cloned into pCADT7 pSCD5:-AD DNA fragment encoding Scd5p (35-872 aa) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pSS14 pMyc-END3A:314 DNA fragment encoding End5p (1-539 aa) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pSS14 pPNIc-SPD3A:314 DNA fragment encoding End5p (1-539 aa) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pSS14 pEND3AC:314 DNA fragment encoding End5p (1-539 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pSS30 (Zeng ad, 2001) pEND3AC:314 DNA fragment encoding End5p (1-539 aa) was placed under its own promoter control in pSS314 (Seng ad, 2001) pCAL-HA-PRK1-316 DNA fragment encoding PAD (16) (1-399 aa) was cloned in frame with the HA epitope and placed under CoAL1 promoter control in pSS314 (Seng ad Cai, 1999) pGLC7-HA-305 DNA fragment encoding PAD (90-393 aa) was cloned in frame with the HA epitope and placed under GAL1 promoter control in pSS314 (Seng ad Cai, 1999) pGLC7-HA-305 DNA fragment encoding PAD (90-393 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pSS30 (Seng ad Cai, 1999) pGLC7-THA-306 DNA fragment encoding PAD (90-393 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pSS30 (Seng ad Cai, 2003) pGLC7-THA-306	pEND3c-BD	DNA fragment encoding Endsp (77-349 a) was cloned into pGBKT7
pSCD5-CAD DNA fragment encoding EdSp (35-872 ia) was cloned info pCADI7 pMyc-END3-314 DNA fragment encoding EdSp (1-349 au) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS314 pMyc-END3A-314 DNA fragment encoding EdBp (1-353 au) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS314 pPANIc-Myc-306 DNA fragment encoding EndBp (1-253 au) was placed under its own promoter control in pRS314 pEND3AC-314 DNA fragment encoding EndBp (1-253 au) was placed under its own promoter control in pRS314 pEND3AC-314 DNA fragment encoding EndBp (1-830 au) was cloned in frame with a C-terminal Myc epitope and placed under GAL promoter control in pRS314 (2eng and Cai, 1999) pGAL-HA-PRK1 ^{D19879-31} DNA fragment encoding PMIp (1-810 au) was cloned in frame with the HA epitope and placed under GAL promoter control in pRS314 (2eng and Cai, 1999) pGEC7-HA-305 DNA fragment encoding PAIp (9-380 au) was cloned in frame with the HA epitope and placed under GAL promoter control in pRS314 (2eng and Cai, 1999) pGLC7-HA-305 DNA fragment encoding Panip (9-380 au) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304 pGLC7-HA-305 DNA fragment encoding Panip (92-380 au) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304 pGLC7-HA-305 DNA fragment encoding Panip (92-380 au) was cloned in frame with a C-terminal Myc	pSCD5-N-AD	DNA fragment encoding Scd5p (1-534 aa) was cloned into pGADI7
PMyc-END3314DNA fragment encoding End3p (1-349 aa) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS314PMyc-END3AC-314DNA fragment encoding End3p (1-534 aa) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS314PPANIc-Myc-306DNA fragment encoding End3p (1-5349 aa) was cloned in frame with an N-terminal Myc epitope followed by the ADH1 terminator in pRS306 (Zeng et al., 2001)PEND3AC-314DNA fragment encoding End3p (1-5349 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS316 (Zeng and Cai, 1999)PGAL-HA-PRK131DNA fragment encoding PR316 (Zeng and Cai, 1999)PGLC7-HA-305DNA fragment encoding PR316 (Zeng and Cai, 1999)PGLC7-HA-305DNA fragment encoding PAn1P (09-383 aa) was cloned in frame with the HA epitope and placed under GAL1 promoter control in pRS316 (Zeng and Cai, 1999)PGLC7-HA-305DNA fragment encoding PAn1P (09-388 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS305 (Zeng and Cai, 1999)PGLC7-Int-306DNA fragment encoding Pan1P (09-388 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS305 (Zeng and Cai, 1999)PGLC7-Int-306PUb-Arg-DHFR*-HA-CLC7n-306; The first 200 bp of the CLC7 optome with a C-terminal Myc epitope followed by the ADH1 terminator in pRS306PGLC7-Int-306PUb-Arg-DHFR*-HA-CLC7n-306; The first 200 bp of the CLC7 optome with a C-terminal Myc epitope followed by the ADH1 terminator in pRS306PGLC7-Int-306PUb-Arg-DHFR*-HA-CLC7n-306; The first 200 bp of the CLC7 optome was generated by PCR and cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminato	pSCD5-C-AD	DNA fragment encoding Scd5p (535-872 aa) was cloned into pGADT7
pMyc-END3AC-314 under its own promoter control in pRS314 pMyc-END3AN-314 DNA fragment encoding End39 (1-253 ag) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS314 pPANIc-Myc-306 DNA fragment encoding End39 (116-349 ag) was cloned in frame with an N-terminal Myc epitope followed by the ADH1 terminator in pRS304 (Zeng and Cai, 1999) pCAL-HA-PRK110187V-316 DNA fragment encoding End39 (116-349 ag) was cloned in frame with the HA epitope and placed under (GAL1 promoter control in pRS316 (Zeng and Cai, 1999) pGAL-HA-PRK110187V-314 DNA fragment encoding PKH10 [1-810 ag) was cloned in frame with the HA epitope and placed under GAL1 promoter control in pRS316 (Zeng and Cai, 1999) pGCX-R1 GST-R1; DNA fragment encoding PAH1 [9-983 ag) was cloned in frame with the HA epitope and placed under GAL1 promoter control in pRS316 (Zeng and Cai, 1999) pGLC7n-td-306 DNA fragment encoding PAH2 (9-983 ag) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS305 pGLC7n-td-306 DNA fragment encoding PAH2 (2C7n-306; The Leu residue at position 60 into pCEX-4T-1 (Zeng and Cai, 1999) pGLC7n-td-306 DNA fragment encoding PAH2 (2C7n-306; The Leu residue at position 60 into pCEX-4T-1 (Zeng and Cai, 1994) pGLC7n-td-306 DNA fragment encoding PAH2 (2C7n-306; The Leu residue at position 60 into pCEX-4T-1 (Zeng and Cai, 1994) pGLC7n-td-306 DNA fragment encoding Scd59 (499-385 ag) was cloned into pCEX-4T-	pMyc-END3-314	DNA fragment encoding End3p (1-349 aa) was cloned in frame with an N-terminal Myc epitope and placed
PMy-END3AC-314 DNA fragment encoding End3p (12-33 aa) was cloned in frame with an N-terminal Myc epitope and placed under its own promoter control in pRS314 PMN-END3AC-314 DNA fragment encoding End3p (116-349 aa) was cloned in frame with an N-terminal Myc epitope followed by the ADH1 terminator in pRS306 (2000) PEND3AN-314 DNA fragment encoding End3p (116-349 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS306 (2000) PEND3AN-314 DNA fragment encoding End3p (116-349 aa) was cloned under its own promoter control in pRS314 (2000) PGAL-HA-PRK1-716 DNA fragment encoding End3p (116-349 aa) was cloned under its own promoter control in pRS314 (2000) PGAL-HA-PRK1 ^{D158V,214} DNA fragment encoding PrK1p (1480 aa) was cloned under its own promoter control in pRS314 (2000) PGAL-Cr-HA-305 DNA fragment encoding Ch(27) (60-312 aa) was cloned in frame with the HA epitope and placed under its own promoter control in pRS314 (2000) PGLC7-rtd-306 DNA fragment encoding Ch(27) (60-312 aa) was cloned in the DFLR-dT-1 (Zeng and Cai, 1999) PGLC7-rtd-306 DNA fragment encoding Scd59 (16-349 aa) was cloned in the C-terminal Myc epitope followed by the ADH1 terminator in pRS305 PGLC7-rtd-306 DNA fragment encoding Scd59 (409-585 aa) was cloned in the C-terminal Myc epitope followed by the ADH1 terminator in pRS305 PGCL7-rtd-306 DNA fragment encoding Scd59 (79-872 aa) with futations was cloned in frame with a C-terminal Myc epitope followed		under its own promoter control in pRS314
pMy-END3ΔN-314 under its own promoter control in pKS314 pPAN1c-Myc-306 DNA fragment encoding End3p (116-349 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pKS306 (Zeng et al., 2001) pEND3ΔC-314 DNA fragment encoding End3p (1252-1480 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pKS304 (Zeng and Cai, 1999) pGAL-HA-PRK1 ^{D158V,314} DNA fragment encoding PK1p (1-810 aa) with D158Y mutation was cloned in frame with the HA epitope and placed under GAL1 promoter control in pKS314 (Zeng and Cai, 1999) pGLC7-HA-305 DNA fragment encoding PK1p (1-810 aa) with D158Y mutation was cloned in to pCEX-4T-1 (Zeng and Cai, 1999) pGLC7-HA-305 DNA fragment encoding PA1p (99-385 aa) was cloned in to pCEX-4T-1 (Zeng and Cai, 1999) pGLC7-HA-305 DNA fragment encoding PA1p (1252-1480 aa) was cloned in to pCEX-4T-1 (Zeng and Cai, 1999) pGLC7-HA-306 DNA fragment encoding PA1p (1252-1480 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pKS304 pGLC7-HA-306 DNA fragment encoding Scd5p (10-342 aa) was cloned in to pCEX-4T-1 (Huang et al., 2003) pGLC7-HA-306 DUb-Arg-DHFR*-HA-GLC7n-306; The first 200 bp of the CLC7 oper reading frame was generated by PCR and cloned into HindIII site of the plasmid pW668 (He and Moore, 2005) pGLC7-HA-305 DNA fragment encoding Scd5p (490-885 aa) was cloned in to pCEX-4T-1 (Huang et al., 2003) pSC	pMyc-END3∆C-314	DNA fragment encoding End3p (1-253 aa) was cloned in frame with an N-terminal Myc epitope and placed
pMyC=ND5AN-314DNA fragment encoding Endsp (110-39 a) was cloned in frame with a C-terminal Myc epitope and placed under its own promoter control in pR5314pPANIc-Myc-306DNA fragment encoding Endsp (1-233 a) was placed under its own promoter control in pR5314pEND3AN-314DNA fragment encoding Endsp (1-249 a) was placed under its own promoter control in pR5314pGAL-HA-PKK1-513DNA fragment encoding Endsp (1-430 a) was cloned in frame with the HA epitope and placed under cAL1 promoter control in pR5314 (Zeng and Cai, 1999)pGAL-HA-PKK10587-314DNA fragment encoding Prk1p (1-810 a) was cloned in frame with the HA epitope and placed under cAL1 promoter control in pR5314 (Zeng and Cai, 1999)pGLC7-HA-305DNA fragment encoding Clorp (6-312 a) with its upstream 50 base pairs (bp) of the intron was cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pR5305pGLC7-n4d-306DNA fragment encoding Clorp (6-312 a) with its upstream 50 base pairs (bp) of the intron was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pR5305pGLC7-n4d-306DNA fragment encoding Scd59 (409-585 a) was cloned in to DEFX-47-1 (Huang et al., 2003)pGEX-SCD5 ^{WT} SCT-SCD5 variant with T166, T450A, T490A mutations was cloned into pGEX-47-1 (Huang et al., 2003)pSCD5-FMA-316The SCD5 gene was generated by PCR and cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pR5305pSCD5-FMA-343DNA fragment encoding Scd59 (49-585 a) was cloned into pGEX-47-1 (Huang et al., 2003)pSCD5-FMA-343DNA fragment encoding Scd59 (49-582 a) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pR5305pSCD5-FMA-343DNA fragment encodi		under its own promoter control in pRS314
pPAN1c-Myc-306 DNA fragment encoding Pan1p (1252-1480 a) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pR5316 (Zeng at al., 2001) pEND3AC-314 DNA fragment encoding End5p (1-233 a) was placed under its own promoter control in pR5314 pEND3AC-314 DNA fragment encoding End5p (1-233 a) was placed under its own promoter control in pR5314 pCAL-HA-PRK12 DNA fragment encoding Pan1p (1252-1480 a) was cloned in frame with the HA epitope followed by the ADH1 terminator in pR5305 pGLC7n+td-306 DNA fragment encoding Pan1p (1252-1480 a) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pR5305 pGLC7n+td-306 DV-Arg-DHFR®-HA-GLC7n-306; The first 200 bp of the GLC7 open reading frame was generated by PCR and cloned into FMGU FRA-GLC7n-306 by PCR mutagenesis pGLC7n+td-306 DV-Arg-DHFR®-HA-GLC7n-306; The first 200 bp of the GLC7 open reading frame was generated by PCR and cloned into FMGU FRA-GLC7n-306; The Care position for into PGEX-4T-1 (Huang et al., 2003) pGLC57h4A-305 GST-SCD5; DNA fragment encoding Scd5p (79-872 a) with mutations (Huang et al., 2003) pSCD54MA-316 DNA fragment encoding Scd5p (79-872 a) with mutations was cloned into pGEX-4T-1 (Huang et al., 2003) pSCD55MA-45 GST-SCD5; DNA fragment encoding Scd5p (79-872 a) with mutations was cloned into pGEX-4T-1 (Huang et al., 2003) pSCD54MA-316 DNA fragment encoding Scd5p (79-872 a) with mutations was cloned into pGEX/T7 DNA fragment encoding Scd5p (79-872 a) wi	pMyc-END3ΔN-314	DNA fragment encoding End3p (116-549 aa) was cloned in frame with an N-terminal <i>Myc</i> epitope and
Physical and the second seco	pPAN1c-Myc-306	placed under its own promoter control in pN5514
pEND3AC-314DNA fragment encoding End3p (1-23 aa) was placed under its own promoter control in pRS314pEND3AN-314DNA fragment encoding End3p (1-510 aa) was cloned in frame with the <i>HA</i> epitope and placed under <i>GAL1</i> promoter control in pRS316 (Zeng and Cai, 1999)pGAL-HA-PRK1-316DNA fragment encoding Prk1p (1-810 aa) was cloned in frame with the <i>HA</i> epitope and placed under <i>GAL1</i> promoter control in pRS314 (Zeng and Cai, 1999)pGEX-LR1DNA fragment encoding Prk1p (1-810 aa) was cloned into pGEX-4T-1 (Zeng and Cai, 1999)pGLC7-HA-305GST-LR1; DNA fragment encoding Pra1p (99-383 aa) was cloned into pGEX-4T-1 (Zeng and Cai, 1999)pGLC7-HA-305DNA fragment encoding Pra1p (99-383 aa) was cloned into pGEX-4T-1 (Zeng and Cai, 1999)pGLC7-HA-305TI52K mutation was introduced into pGLC7-HA-305 by PCR mutagenesispPAN1c-Myc-304DNA fragment encoding Pan1p (1252-1480 aa) was cloned into frame with a C-terminal <i>Myc</i> epitope followed by the <i>ADH1</i> terminator in pRS305pGLC7n-td-306PUb-Arg-DHFR®-HA-GLC7n-306; The first 200 bp of the GLC7 open reading frame was generated by PCR and cloned into hid111 site of the plasmid pTW66R (He and Moore, 2005)pGEX-SCD5 ^{YAA} GST-SCD5; DNA fragment encoding Scd5p (79-872 aa) with mutations on its 2nd PT-binding motif (KKVRF to AKAAA) was cloned in frame with a C-terminal <i>HA</i> epitope followed by the <i>ADH1</i> terminator in pRS305pGLC7 ^{T152k} C-Myc-304DNA fragment encoding Scd5p (79-872 aa) with T146A, T450A, T490A mutations was cloned into pGBKT7pSCD5 ^{FMAA} DNA fragment encoding Scd5p (79-872 aa) with T146A, T450A, T490A mutations was cloned into pGBKT7pSCD5 ^{FMAA} -N-BDDNA fragment encoding Scd5p (1-534 aa) with T146A, T450A, T490A mutations was cloned into pGBKT7	pi Aivie-wye-500	by the ADH1 terminator in $DRS36$ (Zeng et al. 2001)
pEND3AN-314 DNA fragment encoding End3p (116-349 aa) was placed under its own promoter control in pRS314 pGAL-HA-PRK1-316 DNA fragment encoding Prk1p (1-810 aa) was cloned in frame with the HA epitope and placed under GAL1 promoter control in pRS314 (Zeng and Cai, 1999) pGLV-FLA-305 DNA fragment encoding Prk1p (1-810 aa) with D158Y mutation was cloned in frame with the HA epitope and placed under GAL1 promoter control in pRS314 (Zeng and Cai, 1999) pGLC7-FLA-305 DNA fragment encoding GCP (60-312 aa) with is upstream 501 base pairs (bp) of the intron was cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS305 pGLC7-ntd-306 DNA fragment encoding Pan1p (92-38 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304 pGLC7n-td-306 DNA fragment encoding SCD5 (The first 200 bp of the GLC7 open reading frame was generated by PCR and cloned in to HindIII site of the plasmid pPW66R (He and Moore, 2005) pGLC7n-td-306 pUb-Arg-DHFR*-HA-GLC7n-306. The first 200 bp of the DH2 reminator in pRS304 pSCD5^MA2 GST-SCD5 SDNA fragment encoding SCd5p (40-385 aa) was cloned in to pCEX-4T-1 (Huang et al., 2003) pSCD5/MA2-1HA-305 DNA fragment encoding SCd5p (79-872 aa) with mutations on its 2nd PP1-binding motif (KKVRF to AXAAA) was cloned in frame with a C-terminal MA epitope followed by the ADH1 terminator in pRS305 pSCD5/MA2-34 DNA fragment encoding Scd5p (1-534 aa) with T146A, T450A, T490A mutations was cloned in to pGBKT7 <t< td=""><td>pEND3AC-314</td><td>DNA fragment encoding End3p (1-253 a) was placed under its own promoter control in pRS314</td></t<>	pEND3AC-314	DNA fragment encoding End3p (1-253 a) was placed under its own promoter control in pRS314
pGAL-HA-PRK1-316DNA fragment encoding Prk1p (1-810 a) was cloned in frame with the <i>HA</i> epitope and placed under <i>GAL1</i> promoter control in pRS316 (Zeng and Cai, 1999)pGAL-HA-PRK1D189V_314DNA fragment encoding Prk1p (1-810 a) with D158Y mutation was cloned in frame with the <i>HA</i> epitope and placed under <i>GAL1</i> promoter control in pRS314 (Zeng and Cai, 1999)pGEX-LR1DNA fragment encoding Prk1p (1-810 a) with D158Y mutation was cloned in frame with the <i>HA</i> epitope and placed under <i>GAL1</i> promoter control in pRS314 (Zeng and Cai, 1999)pGEX-LR1ST-LR1, DNA fragment encoding Prahp (9-938) a) was cloned in to pGEX-4T-1 (Zeng and Cai, 1999)pGLC7 ^{T152K} c-HA-305T152K mutation was introduced into pCLC7c-HA-305 by PCR mutagenesispPAN1c-Myc-304DNA fragment encoding Prahp (9-22-1480 a) was cloned in frame with a C-terminal <i>My</i> epitope followed by the <i>ADH1</i> terminator in pRS304pGLC7n-td-306PUb-Arg-DHFR*-HA-GLC7n-306; The first 200 bp of the GLC7 open reading frame was generated by PCR and cloned into HIIIII site of the plasmid pTW66R (He and Moore, 2005)pGEX-SCD5 ^{WT} GST-SCD5; DNA fragment encoding Scd5p (409-585 aa) was cloned into pGEX-4T-1 (Huang <i>et al.</i> , 2003)pGSCD5 ^{FIBM22_+} HA-316GST-SCD5 gene was generated by PCR and cloned in frame with a C-terminal <i>HA</i> epitope followed by the <i>ADH1</i> terminator in pRS305pGCD7 ^{T152K} c-Myc-304DNA fragment encoding Scd5p (79-872 aa) with mutations on its 2nd PP1-binding motif (KKVRF to AKAAA) was cloned in frame with a C-terminal <i>HA</i> epitope followed by the <i>ADH1</i> terminator in pRS305pSCD5-Mx-34DNA fragment encoding Scd5p (79-872 aa) with T152K mutations was cloned into pGBKT7pSCD5 ^{FAAA-} N-BDDNA fragment encoding Scd5p (1-534 aa) with T1	$pEND3\Delta N-314$	DNA fragment encoding End3p (116-349 a) was placed under its own promoter control in pRS314
GALI promoter control in pRS316 (Zeng and Cai, 1999)pGAL-HA-PRK1DISSY-314DNA fragment encoding Pahp (99-383 aa) was cloned into pGEX-4T-1 (Zeng and Cai, 1999)pGEX-LR1GST-LR1, DNA fragment encoding GL7 (60-312 aa) with its upstream 501 base pairs (bp) of the intron was cloned inpGLC7-HA-305DNA fragment encoding GL7 (60-312 aa) with its upstream 501 base pairs (bp) of the intron was cloned inpGLC7-HA-305DNA fragment encoding Pahp (1252-1480 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304pGLC7-ntd-306pUb-Arg-DHFR*-HA-GLC7n-306; The first 200 bp of the GLC7 open reading frame was generated by PCR and cloned into HindIII site of the plasmid pPW668 (He and Moore, 2005)pGLC5-ntd-306pUb-Arg-DHFR*-HA-GLC7n-306; The first 200 bp of the GLC7 open reading frame was generated by PCR and cloned into HindIII site of the plasmid pPW668 (He and Moore, 2005)pGEX-SCD5 ^{WT} pGEX-SCD5 ^{WT} pGEX-SCD5 DNA fragment encoding Scd5p (09-855 aa) was cloned into pGEX-4T-1 (Huang et al., 2003)pGEX-SCD5 ^{WT} pSCD5-HA-316The SCD5 gene was generated by PCR and cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS306pSCD5FWA2-AHA-305DNA fragment encoding Scd5p (79-872 aa) with mutations on its 2nd PPI-binding motif (KKVRF to AKAAA) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS305pSCD5FMA2-AN-3DDDNA fragment encoding Scd5p (79-872 aa) with mutations was cloned into pGEXT 	pGAL-HA-PRK1-316	DNA fragment encoding Prk1p (1-810 aa) was cloned in frame with the HA epitope and placed under
pGAL-HA-PRK1DNA fragment encoding Prk1p (1-810 a) with D158Y mutation was cloned in frame with the HA epitope and placed under GAL1 promoter control in pRS314 (Zeng and Cai, 1999)pGEX-LR1GST-LR1; DNA fragment encoding Pan1p (99-383 a) was cloned into pGEX-T1-1 (Zeng and Cai, 1999)pGLC7^T152K-CHA-305DNA fragment encoding GlC7p (60-312 a) with its upstream 501 base pairs (bp) of the intron was cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS305pGLC7T152K-CHA-305T152K mutation was introduced into pGLC7-CHA-305 by PCR mutagenesispGLC7n-td-306PUb-Arg-DHFR+HA-GLC7n-306; The first 200 bp of the GLC7 open reading frame was generated by PCR and cloned into HindIII site of the plasmid pPW66R (He and Moore, 2005)pGLC7n-ntd-306pUb-Arg-DHFR+HA-GLC7n-306; The Leu residue at position 66 in the DHFR moiety (Dohmen et al., 1994) of pUb-Arg-DHFR+HA-GLC7n-306; The Leu residue at position 66 in the DHFR moiety (Dohmen et al., 1994) of pUb-Arg-DHFR+HA-GLC7n-306; The Leu residue at position 66 in the DHFR moiety (Dohmen et al., 1994) of pUb-Arg-DHFR+HA-GLC7n-306 matching the data et al., 2003)pGEX-SCD5^MAGST-SCD5; DNA fragment encoding Scd5p (09-872 aa) was cloned into pGEX-4T-1 (Huang et al., 2003) GST-SCD5 variant with T416A, T450A, T490A mutations on its 2nd PP1-binding motif (KKVRF to AKAAA) was cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS305pSCD5pSCD5^AAA-N-BDDNA fragment encoding Scd5p (79-872 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304 DNA fragment encoding Scd5p (79-872 aa) was cloned in frame with a C-terminal MSC epitope followed by the ADH1 terminator in pRS304 DNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutation		GAL1 promoter control in pRS316 (Zeng and Cai, 1999)
geEx-LR1 pGEX-LR1 pGLC7c-HA-305and placed under GAL1 promoter control in pRS314 (Zeng and Cai, 1999)pGEX-LR1 pGLC7c-HA-305GST-LR1; DNA fragment encoding PanD (9)-383 a) was cloned into pGEX-4T-1 (Zeng and Cai, 1999)pGLC7^TI32K_c-HA-305DNA fragment encoding ClC7p (60-312 a) with its upstream 501 base pairs (bp) of the intron was cloned in frame with a C-terminal <i>HA</i> epitope followed by the <i>ADH1</i> terminator in pRS304pGLC7n-td-306PUb-Arg-DHFR*-HA-GLC7n-306; The fuer scilulation was introduced into pGLC70-306 (Fe plasmid pPW66R (He and Moore, 2005)pGLC7n-td-306pUb-Arg-DHFR*-HA-GLC7n-306; The Leu residue at position 66 in the DHR moiety (Dohmen <i>et al.</i> , 1994) of pUb-Arg-DHFR*-HA-GLC7n-306 (mag class) (Web-585 a) was cloned into pGEX-4T-1 (Huang <i>et al.</i> , 2003)pGEX-SCD5 ^{WT} pGEX-SCD5 ^{VAT} GST-SCD5 variant with T416A, T450A, T490A mutations on its 2nd PP1-binding motif (KKVRF to DNA fragment encoding Scd5p (09-872 a) was cloned in to pGEX-4T-1 (Huang <i>et al.</i> , 2003)pSCD5-HA-316The SCD5 gene was generated by PCR and cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS305pSCD5 ^{FIMAD2A} -HA-305DNA fragment encoding Scd5p (09-872 a) was cloned into pGEX-4T-1 (Huang <i>et al.</i> , 2003)pSCD5-Myc-304DNA fragment encoding Scd5p (19-872 a) with mutations on its 2nd PP1-binding motif (KKVRF to DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490A mutations was cloned into pGBKT7pSCD5 ^{AAAA} -N-BDDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490A mutations was cloned into pGBKT7pSCD5 ^{AAAA} -N-BDDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490A mutations was cloned into pGBKT7pSCD5 ^{AAAA} -N-BDDNA fragment encoding Scd5	pGAL-HA-PRK1 ^{D158Y} -314	DNA fragment encoding Prk1p (1-810 aa) with D158Y mutation was cloned in frame with the HA epitope
 pGLZ7-HA-305 pGLZ7-HA-306 pGLZ7-HA-307 pGLZ7-HA-307 pGLZ7-HA-306 pGLZ7-HA-307 pGLZ7-HA-307 pGLZ7-HA-308 pGLZ7	CEV LB4	and placed under GAL1 promoter control in pRS314 (Zeng and Cai, 1999)
 PGLC7^{T152K}-FHA-305 PGLC7^{T152K}-CHA-305 PGLC7^{T152K}-CHA-305 PGLC7^{T152K}-CHA-305 PGLC7^{T152K}-CHA-305 PGLC7^{T152K}-CHA-306 PGL^{T152K}-CHA-306 PGL^{T1152K}-CHA-306 PGL^{T1152K}-CHA-306 PGL^{T1152K}-CHA-306 PGL^{T1152K}-CHA-306 PGL^{T1152K}-CHA-306 PGL^{T1152K}-CHA-306 PGL^{T1152K}-CHA-306 PGL^{T1152K}-CHA-306 PGL^{T11}	PGEX-LKI	GS1-LKI; DNA fragment encoding PanIp (99-383 aa) was cloned into pGEX-41-1 (Zeng and Cal, 1999) DNA fragment encoding Cloze (0.212) and the unstream follower prior (b) of the intervent encoding
pGLC7 ^{T152k} c-HA-305Thick mutation was introduced into pGLC7c-HA-305 by PCR mutagenesispPAN1c-Myc-304T152K mutation was introduced into pGLC7c-HA-305 by PCR mutagenesispGLC7n-td-306pUb-Arg-DHFR*-HA-GLC7n-306; The first 200 bp of the GLC7 open reading frame was generated by PCR and cloned into HindIII site of the plasmid pPW66R (He and Moore, 2005)pGLC7n-td-306pUb-Arg-DHFR*-HA-GLC7n-306; The Leu residue at position 66 in the DHFR moiety (Dohmen et al., 1994)of pUb-Arg-DHFR*-HA-GLC7n-306; The Leu residue at position 66 in the DHFR moiety (Dohmen et al., 2003)pGEX-SCD5 ^{WAT} GST-SCD5 pNA fragment encoding Scd5p (490-585 aa) was cloned into pGEX-4T-1 (Huang et al., 2003)pGEX-SCD5 ^{AAA} GST-SCD5 variant with T416A, T450A, T490A mutations on its 2nd PP1-binding motif (KKVRF to ACAAA) was cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS305pSCD5 ^{PBM2Δ} -HA-305DNA fragment encoding Scd5p (79-872 aa) with T146A, T450A, T490A mutations was cloned into pGBK77pSCD5 ^{AAA} -N-BDDNA fragment encoding Scd5p (1-534 aa) with T146A, T450A, T490A mutations was cloned into pGBK77pSCD5 ^{AAA} -N-ADDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGBK77pSCD5 ^{CEEE} -N-ADDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGBK77pSCD5 ^{CEEE} -N-ADDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGBK77pSCD5 ^{CEEE} -N-ADDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGBK77pSCD5 ^{CEEE} -N-ADDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGBK77	pGLC/C-HA-505	DNA fragment encount generation ($60-512$ a) with its upstream 501 base pairs ($60)$ of the infront was cloned in fragment that 2.5 coming H_{2} and 60 by the 4DH1 terminator in pPS305
pPANIc-Myc-304DNA fragment encoding Pan1p (1252-1480 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304pGLC7n-td-306pUb-Arg-DHFR*-HA-GLC7n-306; The first 200 bp of the GLC7 open reading frame was generated by PCR and cloned into HindIII site of the plasmid pPW66R (He and Moore, 2005)pGLC7n-td-306pUb-Arg-DHFR*-HA-GLC7n-306; The Leu residue at position 66 in the DHFR moiety (Dohmen et al., 1994) of pUb-Arg-DHFR*-HA-GLC7n-306; The Leu residue at position 66 in the DHFR moiety (Dohmen et al., 2003)pGEX-SCD5^AnApSCD5-MA-316pGEX-SCD5ST-SCD5; DNA fragment encoding Scd5p (409-855 aa) was cloned into pGEX-4T-11 (Huang et al., 2003)pSCD5-HA-316The SCD5 gene was generated by PCR and cloned in frame with a C-terminal HA epitope followed by the 	pGLC7 ^{T152K} c-HA-305	T152K mutation was introduced into pGLOZe-HA-305 by PCR mutation in pK0005
by the ADH1 terminator in pR5304by the ADH1 terminator in pR5304pGLC7n-td-306pUb-Arg-DHFR*-HA-GLC7n-306; The first 200 bp of the GLC7 open reading frame was generated by PCR and cloned into HindIII site of the plasmid pPW66R (He and Moore, 2005)pGLC7n-ntd-306pUb-Arg-DHFR*-HA-GLC7n-306; The Leu residue at position 66 in the DHFR moiety (Dohmen <i>et al.</i> , 1994) of pUb-Arg-DHFR*-HA-GLC7n-306; The Leu residue at position 66 in the DHFR moiety (Dohmen <i>et al.</i> , 2003)pGEX-SCD5 ^{VNT} GST-SCD5 variant with T416A, T450A, T490A mutations (Huang <i>et al.</i> , 2003)pSCD5-HA-316The SCD5 gene was generated by PCR and cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pR5316pSCD5-FMA-305DNA fragment encoding Scd5p (79-872 a) with mutations on its 2nd P1-binding motif (KKVRF to AKAAA) was cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pR5305pSCD5-Myc-304DNA fragment encoding Scd5p (79-872 a) with mutations was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pR5305pSCD5-Myc-304DNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 pSCD5EEE_N-NBDpSCD5-A^AA-N-ADDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490E mutations was cloned into pGADT7 pSCD5EEE_N-ADpSLC7-ANDDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490E mutations was cloned into pGADT7 pSCD5EEE_N-ADpSLC7-ANDDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490E mutations was cloned into pGADT7 pSCD5EEE_N-ADpSLC7-ANDDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 pSCD5EEE_N-ADpSLC7-	pPAN1c-Myc-304	DNA fragment encoding Pan1p (1252-1480 aa) was cloned in frame with a C-terminal Muc epitope followed
pGLC7n-td-306pUb-Arg-DHFR*-HA-GLC7n-306; The first 200 bp of the <i>GLC7</i> open reading frame was generated by PCR and cloned into HindIII site of the plasmid pPW66R (He and Moore, 2005)pGLC7n-ntd-306pUb-Arg-DHFR*-HA-GLC7n-306; The Leu residue at position 66 in the DHFR moiety (Dohmen <i>et al.</i> , 1994) of pUb-Arg-DHFR*-HA-GLC7n-306 was changed into Pro by PCR mutagenesispGEX-SCD5 ^{WT} GST-SCD5; DNA fragment encoding Scd5p (49)-585 aa) was cloned into pGEX-4T-1 (Huang <i>et al.</i> , 2003)pGEX-SCD5 ^{MAA} The SCD5 gene was generated by PCR and cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS316pSCD5 ^{PBM2Δ} -HA-305DNA fragment encoding Scd5p (79-872 aa) with mutations on its 2nd PP1-binding motif (KKVRF to AKAAA) was cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS305pSCD5 ^{C-Myc-304} DNA fragment encoding Scd5p (79-872 aa) with mutations was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304pSCD5 ^{AAA} -N-BDDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 pSCD5 ^{AAA} -N-ADpSCD5 ^{AAA} -N-ADDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 pSCD5 ^{AAA} -N-ADpGLC7-BDThe GLC7 coding region was generated by PCR and cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminator in pRS304pSCD5 ^{AAA} -N-ADDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 pSCD5 ^{AAA} -N-ADpGLC7-BDThe GLC7 coding region was generated by PCR and cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminator in pRS304pPK1c-GFP-305DNA fragment	I	by the <i>ADH1</i> terminator in pRS304
and cloned into HindIII site of the plasmid pPW66R (He and Moore, 2005)pGLC7n-ntd-306pUb-Arg-DHFR-HA-GLC7n-306; The Leu residue at position 66 in the DHFR moiety (Dohmen et al., 1994)of pUb-Arg-DHFR*-HA-GLC7n-306 was changed into Pro by PCR mutagenesispGEX-SCD5 ^{WT} GST-SCD5; DNA fragment encoding Scd5p (409-585 aa) was cloned into pGEX-4T-1 (Huang et al., 2003)pSCD5-HA-316The SCD5 gene was generated by PCR and cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS316pSCD5-FBM2A-HA-305DNA fragment encoding Scd5p (79-872 aa) with mutations on its 2nd PP1-binding motif (KKVRF to AKAAA) was cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS305pSCD5-Myc-304DNA fragment encoding Scd5p (79-872 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304pSCD5 ^{5AAA} -N-BDDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7pSCD5 ^{5AAA} -N-ADDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7pSCD5 ^{5AAA} -N-ADDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490A mutations was cloned into pGADT7pGLC7-BDThe GLC7 coding region was generated by PCR and cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminator in pRS305pPRK1c-GFP-304DNA fragment encoding Prk1p (1-810 aa) was generated by PCR and cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminator in pRS305pPRK1c-GFP-304DNA fragment encoding Prk1p (1-324 aa) with T416A, T450A, T490A mutations was cloned into pGADT7pPRK1c-GFP-304DNA fragment encoding Prk1p (1-252-1480 aa) was	pGLC7n-td-306	pUb-Arg-DHFR ^{ts} -HA-GLC7n-306; The first 200 bp of the <i>GLC7</i> open reading frame was generated by PCR
pGLC7n-ntd-306pUb-Arg-DHFR-HA-GLC7n-306; The Leu residue at position 66 in the DHFR moiety (Dohmen et al., 1994) of pUb-Arg-DHFR*-HA-GLC7n-306 was changed into Pro by PCR mutagenesispGEX-SCD5GST-SCD5; DNA fragment encoding Scd5p (409-585 aa) was cloned into pGEX-4T-1 (Huang et al., 2003)pSCD5-HA-316GST-SCD5; DNA fragment encoding Scd5p (409-585 aa) was cloned into pGEX-4T-1 (Huang et al., 2003)pSCD5-HA-316The SCD5 gene was generated by PCR and cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS316pSCD5-PBM2A-HA-305DNA fragment encoding Scd5p (79-872 aa) with mutations on its 2nd PP1-binding motif (KKVRF to AKAAA) was cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS305pSCD5-Myc-304DNA fragment encoding Scd5p (79-872 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304pSCD5^AAA-N-BD pSCD5^AAA-N-ADDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGBKT7 pSCD5^AAA-N-ADpGLC7-BD pGLC7-BDDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding PK1p (1-810 aa) was generated by PCR and placed under GAL1 promoter control in pRS313pPRK1c-GFP-305DNA fragment encoding PRK1p (1439-810 aa) was cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminator in pRS304pPAN1c-CFP-304DNA fragment encoding PRK1p (1252-1480 aa) was cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminato		and cloned into HindIII site of the plasmid pPW66R (He and Moore, 2005)
 of pUb-Arg-DHFR®-HA-GLC7n-306 was changed into Pro by PCR mutagenesis pGEX-SCD5^{WT} GST-SCD5 DNA fragment encoding Scd5p (409-585 aa) was cloned into pGEX-4T-1 (Huang <i>et al.</i>, 2003) pSCD5-HA-316 The <i>SCD5</i> gene was generated by PCR and cloned in frame with a C-terminal <i>HA</i> epitope followed by the <i>ADH1</i> terminator in pRS316 pSCD5^{PBM2Δ}-HA-305 pGLC7^{T152K}c-Myc-305 pSCD5c-Myc-304 pSCD5^{AAA}-N-BD pSCD5^{AAA}-N-BD pSCD5^{AAA}-N-BD pSCD5^{AAA}-N-AD pSA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 pSCD5^{EEE}-N-AD pSA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGADT7 pGLC7-BD pGAL-PRK1-313 pPRK1c-GFP-305 pNA fragment encoding Prk1p (439-810 aa) was generated by PCR and cloned in frame with a C-terminal <i>GFP</i> epitope followed by the <i>ADH1</i> terminator in pRS305 pPAN1c-CFP-304 pFUR4-424 pF	pGLC7n-ntd-306	pUb-Arg-DHFR-HA-GLC7n-306; The Leu residue at position 66 in the DHFR moiety (Dohmen <i>et al.</i> , 1994)
pGEX-SCD5^AAA pGEX-SCD5GS1-SCD5; DNA fragment encoding Scd5p (409-388 aa) was cloned into pGEX-41-1 (Huang et al., 2003)gGEX-SCD5^AAA pSCD5-HA-316GST-SCD5 variant with T416A, T450A, T490A mutations (Huang et al., 2003)pSCD5PBM2A-HA-305DNA fragment encoding Scd5p (79-872 aa) with mutations on its 2nd PP1-binding motif (KKVRF to AKAAA) was cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS305pSCD5-Myc-305DNA fragment encoding Scd5p (79-872 aa) with T152K mutation was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS305pSCD5-Myc-304DNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 pSCD5^AAA-N-BDpSCD5^AAA-N-BD pSCD5^AAA-N-ADDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 pGLC7-BDpGAL-PRK1-313DNA fragment encoding Prk1p (1-810 aa) was generated by PCR and cloned in frame with a C-terminal <i>GFP</i> epitope followed by the <i>ADH1</i> terminator in pRS305pPAN1c-CFP-305DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal <i>GFP</i> epitope followed by the <i>ADH1</i> terminator in pRS304pFUR4-424The <i>EUR4</i> gene was generated by PCR and cloned into pRS424pFUR4-424The <i>EUR4</i> gene was generated by PCR and cloned into pRS424pFUR4-424The <i>EUR4</i> gene was generated by PCR and cloned into pRS424pFUR4-424The <i>EUR4</i> gene was generated by PCR and cloned into pRS424pFUR4-424The <i>EUR4</i> gene was generated by PCR and cloned into pRS424pFUR4-424The <i>EUR5</i> gene wa		ot pUb-Arg-DHFK ^{ts} -HA-GLC ⁷ n-306 was changed into Pro by PCR mutagenesis
JOEL-SCD5CS1-SCD5 Variant with 1416A, 1450A, 1490A initiations (Haing et al., 2005)pSCD5-HA-316The SCD5 gene was generated by PCR and cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS316pSCD5PBM24_HA-305DNA fragment encoding Scd5p (79-872 a) with mutations on its 2nd PP1-binding motif (KKVRF to AKAAA) was cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS305pGLC7T152Kc-Myc-305DNA fragment encoding Glc7p (60-312 a) with T152K mutation was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS305pSCD5-Avc-304DNA fragment encoding Scd5p (79-872 a) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS305pSCD5^AAA_N-BDDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 pSCD5 ^{AAA_N-N-AD} pSCD5^AAA_N-ADDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 pSCD5 ^{EEE_N-AD} pSCD5^AAA_N-ADDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 pSCD5 ^{EEE_N-AD} pGL27-BDThe GLC7 coding region was generated by PCR and cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminator in pRS305pPRN1c-CFP-304DNA fragment encoding PanIp (1252-1480 aa) was cloned in frame with a C-terminal CFP epitope followed by the ADH1 terminator in pRS304pFUR4-424The FUR4 gene was generated by PCR and cloned into pRS424pFUR4-424The EVD3 gene was generated by PCR and cloned into pRS424pFUR4-424The SCD5 gene was generated by PCR and cloned into pRS424pFUR4-424The SCD5 gene was	pGEX-SCD5 ¹¹	GST-SCD5 using twith T416A T450A T00A mutations (Hung et al. 2002)
PSCD5 PPBM2A-HA-305ADH1 terminator in pRS316pSCD5PPBM2A-HA-305DNA fragment encoding Scd5p (79-872 aa) with mutations on its 2nd PP1-binding motif (KKVRF to AKAAA) was cloned in frame with a C-terminal <i>HA</i> epitope followed by the <i>ADH1</i> terminator in pRS305pSCD5-Myc-304DNA fragment encoding Scd5p (79-872 aa) with T152K mutation was cloned in frame with a C-terminal <i>Myc</i> epitope followed by the <i>ADH1</i> terminator in pRS305pSCD5-Myc-304DNA fragment encoding Scd5p (79-872 aa) was cloned in frame with a C-terminal <i>Myc</i> epitope followed by the <i>ADH1</i> terminator in pRS304pSCD5^AAA-N-BDDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 pSCD5 ^{AAA} -N-ADpSCD5 ^{AAA} -N-ADDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 pSCD5 ^{EEE} -N-ADpSCL7-BDDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 pGLC7-BDpGAL-PRK1-313DNA fragment encoding Prk1p (1-810 aa) was generated by PCR and cloned in frame with a C-terminal <i>GFP</i> epitope followed by the <i>ADH1</i> terminator in pRS305pPAN1c-CFP-304DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal <i>GFP</i> epitope followed by the <i>ADH1</i> terminator in pRS304pFUR4-424The <i>FUR4</i> gene was generated by PCR and cloned in frame with a C-terminal <i>CFP</i> epitope followed by the <i>ADH1</i> terminator in pRS304pFUR4-424The <i>FUR4</i> gene was generated by PCR and cloned into pRS424pFUR4-424The <i>FUR4</i> gene was generated by PCR and cloned into pRS424pFUR4-424The <i>FUR3</i> gene was generated by PCR and cloned into pRS424pFUR3-424The <i>SCD5</i> gene was generat	pGEA-SCDS pSCD5-HA-316	G51-5CD5 gene was generated by PCR and cloned in frame with a C-terminal HA enitope followed by the
pSCD5 ^{PBM24} -HA-305DNA fragment encoding Scd5p (79-872 aa) with mutations on its 2nd PP1-binding motif (KKVRF to AKAAA) was cloned in frame with a C-terminal <i>HA</i> epitope followed by the <i>ADH1</i> terminator in pRS305pGLC7 ^{T152K} c-Myc-305DNA fragment encoding Glc7p (60-312 aa) with T152K mutation was cloned in frame with a C-terminal <i>Myc</i> epitope followed by the <i>ADH1</i> terminator in pRS305pSCD5c-Myc-304DNA fragment encoding Scd5p (79-872 aa) was cloned in frame with a C-terminal <i>Myc</i> epitope followed by the <i>ADH1</i> terminator in pRS304pSCD5 ^{AAA} -N-BDDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 	p5CD5 111 510	ADH1 terminator in pRS316
AKAAA) was cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS305pGLC7 ^{T152K} c-Myc-305DNA fragment encoding Glc7p (60-312 aa) with T152K mutation was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS305pSCD5c-Myc-304DNA fragment encoding Scd5p (79-872 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304pSCD5^AAA-N-BDDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGBKT7 pSCD5 ^{EEE-} N-ADpSCD5^AAA-N-ADDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 pGLC7-BDpGLC7-BDDNA fragment encoding Prk1p (1-580 aa) was generated by PCR and cloned in frame into pGBKT7 DNA fragment encoding Prk1p (1-810 aa) was generated by PCR and placed under GAL1 promoter control in pRS313pPRK1c-GFP-305DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminator in pRS305pFUR4-424DNA fragment encoding Pan1p (1252-1480 aa) was cloned in frame with a C-terminal CFP epitope followed by the ADH1 terminator in pRS304pFUR4-424The FUR4 gene was generated by PCR and cloned into pRS424pFUR4-424The END3 gene was generated by PCR and cloned into pRS424pFUR3-424The SCD5 gene was generated by PCR and cloned into pRS424pSCD5-424The SCD5 gene was generated by PCR and cloned into pRS424	pSCD5 ^{PBM2Δ} -HA-305	DNA fragment encoding Scd5p (79-872 aa) with mutations on its 2nd PP1-binding motif (KKVRF to
pGLC7 ^{T152k} c-Myc-305DNA fragment encoding Glc7p (60-312 aa) with T152K mutation was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS305pSCD5c-Myc-304DNA fragment encoding Scd5p (79-872 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304pSCD5^AAA-N-BDDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGBKT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding PrK1p (1-810 aa) was generated by PCR and cloned in frame with a C-terminal <i>GFP</i> epitope followed by the <i>ADH1</i> terminator in pRS305pPRK1c-GFP-305DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal <i>GFP</i> epitope followed by the <i>ADH1</i> terminator in pRS305pFUR4-424DNA fragment encoding Pan1p (1252-1480 aa) was cloned in frame with a C-terminal <i>CFP</i> epitope followed by the <i>ADH1</i> terminator in pRS304pFUR4-424The <i>FUR4</i> gene was generated by PCR and cloned into pRS424pFUR4-424The <i>END3</i> gene was generated by PCR and cloned into pRS424pFUR4-24The <i>SCD5</i> gene was generated by PCR and cloned into pRS424pFUR4-24The <i>SCD5</i> gene was generated by PCR and cloned into pRS424	1	AKAAA) was cloned in frame with a C-terminal HA epitope followed by the ADH1 terminator in pRS305
Myc epitope followed by the ADH1 terminator in pRS305pSCD5c-Myc-304DNA fragment encoding Scd5p (79-872 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304pSCD5^AAA-N-BDDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 pSCD5^EEE-N-BDpSCD5^AAA-N-ADDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 DNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGADT7 pSCD5^EEE-N-ADpSCD5^EEE-N-ADDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 pGLC7-BDpGLC7-BDThe GLC7 coding region was generated by PCR and cloned in frame into pGBKT7 DNA fragment encoding Prk1p (1-810 aa) was generated by PCR and placed under GAL1 promoter control in pRS313pPRK1c-GFP-305DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminator in pRS304pFUR4-424The FUR4 gene was generated by PCR and cloned into pRS424pEND3-424The FUR4 gene was generated by PCR and cloned into pRS424pSCD5-424The SCD5 gene was generated by PCR and cloned into pRS424	pGLC7 ^{T152K} c-Myc-305	DNA fragment encoding Glc7p (60-312 aa) with T152K mutation was cloned in frame with a C-terminal
pSCD5c-Myc-304DNA fragment encoding Scd5p (79-872 aa) was cloned in frame with a C-terminal Myc epitope followed by the ADH1 terminator in pRS304pSCD5^AAA-N-BDDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 pGLC7-BDpGLC7-BDDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7 DNA fragment encoding Prk1p (1-810 aa) was generated by PCR and cloned in frame with a C-terminal <i>GFP</i> epitope followed by the <i>ADH1</i> terminator in pRS305pPRK1c-GFP-305DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal <i>CFP</i> epitope followed by the <i>ADH1</i> terminator in pRS304pFUR4-424The <i>FUR4</i> gene was generated by PCR and cloned into pRS424pEND3-424The <i>FUR4</i> gene was generated by PCR and cloned into pRS424pSCD5-424The <i>SCD5</i> gene was generated by PCR and cloned into pRS424		<i>Myc</i> epitope followed by the <i>ADH1</i> terminator in pRS305
by SCD5^AAA-N-BDDNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGBKT7pSCD5DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGBKT7pSCD5DNA fragment encoding Scd5p (1-534 aa) with T416A, T450A, T490A mutations was cloned into pGADT7pSCD5DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7pSCD5DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7pGLC7-BDDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7pGAL-PRK1-313DNA fragment encoding Prk1p (1-810 aa) was generated by PCR and cloned in frame into pGBKT7pPRK1c-GFP-305DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal <i>GFP</i> epitope followed by the <i>ADH1</i> terminator in pRS304pFUR4-424The <i>FUR4</i> gene was generated by PCR and cloned into pRS424pEND3-424The <i>FUR4</i> gene was generated by PCR and cloned into pRS424pSCD5-424The <i>SCD5</i> gene was generated by PCR and cloned into pRS424	pSCD5c-Myc-304	DNA fragment encoding Scd5p (79-872 aa) was cloned in frame with a C-terminal Myc epitope followed by
pSCD5DNA fragment encoding Scd5p (1-534 aa) with 1416A, 1450A, 1490A mutations was cloned into pGBK17pSCD5DNA fragment encoding Scd5p (1-534 aa) with 1416E, 1450E, 1490E mutations was cloned into pGBK17pSCD5DNA fragment encoding Scd5p (1-534 aa) with 1416E, 1450E, 1490E mutations was cloned into pGADT7pSCD5DNA fragment encoding Scd5p (1-534 aa) with 1416E, 1450E, 1490E mutations was cloned into pGADT7pGLC7-BDDNA fragment encoding Prklp (1-534 aa) with 1416E, 1450E, 1490E mutations was cloned into pGADT7pGL27-BDDNA fragment encoding Prklp (1-810 aa) was generated by PCR and cloned in frame into pGBKT7pGAL-PRK1-313DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal <i>GFP</i> epitope followed by the <i>ADH1</i> terminator in pRS305pPAN1c-CFP-304DNA fragment encoding Pan1p (1252-1480 aa) was cloned into pRS424pFUR4-424The <i>FUR4</i> gene was generated by PCR and cloned into pRS424pEND3-424The <i>END3</i> gene was generated by PCR and cloned into pRS424pSCD5-424The <i>SCD5</i> gene was generated by PCR and cloned into pRS424		the ADH1 terminator in pK5304
DisclosFunctional StatepSCD5PSCD5pSCD5DNA fragment encoding Scd5p (1-534 aa) with T416L, T450L, T490L mutations was cloned into pGADT7pSCD5DNA fragment encoding Scd5p (1-534 aa) with T416L, T450E, T490E mutations was cloned into pGADT7pGLC7-BDDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7pGAL-PRK1-313DNA fragment encoding Prk1p (1-810 aa) was generated by PCR and cloned in frame into pGBKT7pPRK1c-GFP-305DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminator in pRS305pFUR4-424The FUR4 gene was generated by PCR and cloned into pRS424pFUR4-424The FUR4 gene was generated by PCR and cloned into pRS424pEND3-424The END3 gene was generated by PCR and cloned into pRS424pSCD5-424The SCD5 gene was generated by PCR and cloned into pRS424	pSCD5 ^{EEE} -N-BD	DNA fragment encoding Scd5p (1-534 aa) with 1416A, 1450A, 1490A mutations was cloned into pGbK17
PSCD5DNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7pGLC7-BDDNA fragment encoding Scd5p (1-534 aa) with T416E, T450E, T490E mutations was cloned into pGADT7pGAL-PRK1-313DNA fragment encoding Prk1p (1-810 aa) was generated by PCR and cloned in frame into pGBKT7pPRK1c-GFP-305DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal <i>GFP</i> epitope followed by the <i>ADH1</i> terminator in pRS305pFUR4-424DNA fragment encoding Pan1p (1252-1480 aa) was cloned into pRS424pFUR4-424The <i>FUR4</i> gene was generated by PCR and cloned into pRS424pEND3-424The <i>END3</i> gene was generated by PCR and cloned into pRS424pSCD5-424The <i>SCD5</i> gene was generated by PCR and cloned into pRS424	pSCD5 ^{AAA} -N-AD	DNA fragment encoding Sed5n (1-534 a) with 1416A 1450A 1490E mutations was cloned into nCADT7
pGLC7-BDThe GLC7 coding region was generated by PCR and cloned in frame into pGBKT7pGAL-PRK1-313DNA fragment encoding Prk1p (1-810 aa) was generated by PCR and placed under GAL1 promoter control in pRS313pPRK1c-GFP-305DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminator in pRS305pPAN1c-CFP-304DNA fragment encoding Pan1p (1252-1480 aa) was cloned in frame with a C-terminal CFP epitope followed by the ADH1 terminator in pRS304pFUR4-424The FUR4 gene was generated by PCR and cloned into pRS424pEND3-424The END3 gene was generated by PCR and cloned into pRS424 (Tang et al., 1997) The SCD5 gene was generated by PCR and cloned into pRS424	pSCD5 ^{EEE} -N-AD	DNA fragment encoding Scd5p (1-534 a) with T416E, T450E, T490E mutations was cloned into pGADT7
pGAL-PRK1-313DNA fragment encoding Prk1p (1-810 aa) was generated by PCR and placed under GAL1 promoter control in pRS313pPRK1c-GFP-305DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminator in pRS305pPAN1c-CFP-304DNA fragment encoding Pan1p (1252-1480 aa) was cloned in frame with a C-terminal CFP epitope followed by the ADH1 terminator in pRS304pFUR4-424The FUR4 gene was generated by PCR and cloned into pRS424pEND3-424The END3 gene was generated by PCR and cloned into pRS424 (Tang et al., 1997) The SCD5 gene was generated by PCR and cloned into pRS424	pGLC7-BD	The GLC7 coding region was generated by PCR and cloned in frame into pGBKT7
in pRS313pPRK1c-GFP-305DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminator in pRS305pPAN1c-CFP-304DNA fragment encoding Pan1p (1252-1480 aa) was cloned in frame with a C-terminal CFP epitope followed by the ADH1 terminator in pRS304pFUR4-424The FUR4 gene was generated by PCR and cloned into pRS424pEND3-424The END3 gene was generated by PCR and cloned into pRS424 (Tang et al., 1997) The SCD5 gene was generated by PCR and cloned into pRS424	pGAL-PRK1-313	DNA fragment encoding Prk1p (1-810 aa) was generated by PCR and placed under GAL1 promoter control
pPRK1c-GFP-305DNA fragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal GFP epitope followed by the ADH1 terminator in pRS305pPAN1c-CFP-304DNA fragment encoding Pan1p (1252-1480 aa) was cloned in frame with a C-terminal CFP epitope followed by the ADH1 terminator in pRS304pFUR4-424The FUR4 gene was generated by PCR and cloned into pRS424pEND3-424The END3 gene was generated by PCR and cloned into pRS424 (Tang et al., 1997)pSCD5-424The SCD5 gene was generated by PCR and cloned into pRS424		in pRS313
by the ADH1 terminator in pKS305pPAN1c-CFP-304DNA fragment encoding Pan1p (1252-1480 aa) was cloned in frame with a C-terminal CFP epitope followed by the ADH1 terminator in pRS304pFUR4-424The FUR4 gene was generated by PCR and cloned into pRS424pEND3-424The END3 gene was generated by PCR and cloned into pRS424 (Tang et al., 1997)pSCD5-424The SCD5 gene was generated by PCR and cloned into pRS424	pPRK1c-GFP-305	DNA tragment encoding PRK1p (439-810 aa) was cloned in frame with a C-terminal <i>GFP</i> epitope followed
prAINIC-CFF-304DINA fragment encouring Failp (1252-1480 aa) was cloned in frame with a C-terminal CFP epitope followed by the ADH1 terminator in pRS304pFUR4-424The FUR4 gene was generated by PCR and cloned into pRS424pEND3-424The END3 gene was generated by PCR and cloned into pRS424 (Tang et al., 1997)pSCD5-424The SCD5 gene was generated by PCR and cloned into pRS424	DANIA CED 204	by the ADHI terminator in pK5305
pFUR4-424The FUR4 gene was generated by PCR and cloned into pRS424pEND3-424The END3 gene was generated by PCR and cloned into pRS424 (Tang et al., 1997)pSCD5-424The SCD5 gene was generated by PCR and cloned into pRS424	pranic-Cfr-304	by the ADH1 terminator in pRS304
pEND3-424The END3 gene was generated by PCR and cloned into pRS424 (Tang et al., 1997)pSCD5-424The SCD5 gene was generated by PCR and cloned into pRS424	pFUR4-424	The FUR4 gene was generated by PCR and cloned into pRS474
pSCD5-424 The SCD5 gene was generated by PCR and cloned into pRS424	pEND3-424	The END3 gene was generated by PCR and cloned into pRS424 (Tang <i>et al.</i> , 1997)
	pSCD5-424	The SCD5 gene was generated by PCR and cloned into pRS424

oride, 2 mM sodium orthovanadate, 2 mM sodium pyrophosphate, 6 mM β -glycerophosphate) for 2 h before immunoprecipitation was carried out.

Glutathione Transferase (GST) Fusion Proteins and In Vitro Kinase and Phosphatase Assays

To make GST-fusion proteins, DNA fragments were generated by PCR and cloned in-frame into the bacterial GST expression vector pGEX-4T-1 as indicated in Table 2. Expression and purification of GST-fusion proteins followed the published procedure (Zeng and Cai, 1999). Using VIVASPIN 500 columns (Vivascience, Hannover, Germany), GST-fusion proteins were washed and buffer exchanged into either binding buffer (100 mM NaCl, 20 mM HEPES, pH 7.3, 0.1% Triton X-100, and 1 mM dithiothreitol [DTT]) for in vitro binding assay or H2O for protein phosphatase assay. In vitro kinase assays were performed as described previously (Zeng and Cai, 1999) with slight modifications. The beads-conjugated anti-HA antibody was used to immunoprecipitate HA-Prk1p. GST-fusion proteins were mixed with the immunoprecipitated kinase, 60 µl of HBII buffer, 10 µl of 100 mM ATP, and 10 µl of 250 mM 3-(N-morpholino)propanesulfonic acid in a total volume of 200 µl and incubated at 25°C for 3 h, followed by gel electrophoresis and sequential immunoblotting with monoclonal anti-GST (BD Biosciences, Palo Alto, CA) and anti-PThr antibodies. For protein phosphatase assays, yeast extracts containing endogenously expressed Glc7-HA were prepared with phosphatase inhibitor-free lysis buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 7.2, and 1 mM phenylmethylsulfonyl fluoride [PMSF]) supplemented with protease inhibitors (cocktail tablets from Roche Applied Science). Glc7-HA was immunoprecipitated and washed with radioimmunoprecipitation assay buffer (50 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS) five times. The immunoprecipitates, with or without the preincubation with 1 µl of PP1 inhibitor I-2 (New England Biolabs, Ipswich, MA) at 25°C for 15 min, were mixed with phosphorylated GST-fusion proteins and 10 µl of 10× PP1 buffer (New England Biolabs) in a total volume of 100 μ l. The mixture was incubated at 37°C, and 20 µl of supernatant was taken at each time point in 20-min intervals. Samples were then subjected to gel electrophoresis and sequential immunoblotting with anti-GST and anti-PThr antibodies.

Two-Hybrid Interaction and In Vitro Binding Assays

For yeast two-hybrid interaction assays, DNA fragments of SCD5, PAN1, END3, and GLC7 were generated by PCR and cloned into pGBKT7 or pGADT7 vectors as indicated in Table 2. Plasmids were cotransformed into the strain SFY526, and the expression of each fusion protein was confirmed by Western blotting with anti-HA and anti-Myc antibodies. Interactions were quantified by measuring the β -galactosidase activities as instructed by the manufacturer (BD Biosciences). For in vitro binding assays, DNA fragments of SCD5 were generated by PCR and cloned into pET-32a to fuse with an N-terminal His-epitope. The plasmids were transformed into bacterial strain BL21. Transformants were grown to $OD_{600} = 1.0$ and incubated with 1 mM isopropylthio-β-d-galactoside at 37°C overnight. Cells were collected by centrifugation and suspended in cold extraction buffer (1% Triton, 150 mM NaCl, 5 mM imidazole, 20 mM Tris-HCl, pH 8.0, and 1 mM PMSF). The suspensions were sonicated on ice, and lysates were centrifuged at 17,000 rpm for 20 min. The supernatants were incubated with prewashed nickel-nitrilotriacetic acid agarose beads (QIAGEN, Valencia, CA) for 1 h at 4°C. After wash with washing buffer (200 mM NaCl, 20 mM HEPES, pH 7.3, 0.1% Triton X-100, and 1 mM DTT) three times, the beads were incubated with GST-fusion proteins in 500 μl of binding buffer for 1 h at 4°C. The bead-bound proteins were washed with washing buffer five times and subjected to gel electrophoresis and sequential immunoblotting with anti-GST and anti-His antibodies.

Actin Staining and Endocytosis Assay

Staining of actin filaments with rhodamine-phalloidin (Invitrogen, Carlsbad, CA) was performed as described previously (Huang *et al.*, 2003). The uracil permease internalization assay was carried out according to Volland *et al.* (1994) with minor modifications. Yeast cells were transformed with a multicopy plasmid containing the *FUR4* gene to increase the production of uracil permease. The transformants were grown in uracil dropout medium at 25°C to OD₆₀₀ of 0.2–0.3, and then they were incubated at 37°C for 6 h. Cultures were shifted back to 25°C, and cycloheximide was immediately added to a final concentration of 100 μ g/ml. On the addition of cycloheximide, samples were taken at 20-min intervals to assay the uracil permease activity. One milliliter of the culture at each time point was incubated with 5 μ l of uracil solution containing 4.5 μ l of 1 mM uracil and 0.5 μ l of 1 mCi/ml [5,6-³H]uracil (GE Healthcare) for 20 s at 25°C. The mixture was then quickly filtered through a Whatman 25 mm GF/C filter, followed by washing twice with ice-old water and counting for the retained radioactivity.

Live Cell Imaging

Yeast cells expressing GFP and/or cyan fluorescent protein (CFP)-tagged proteins were allowed to grow to early log phase at 30°C. Cells were harvested, resuspended in SC media, and adhered to the surface of a glass slide precoated with 2% agarose. The slide was then covered with a coverslip and

4888

sealed with petroleum jelly. Fluorescence microscopy was performed using a Zeiss Axiovert 200 M microscope equipped with a Coolsnap HQ camera (Roper Scientific, Tucson, AZ). All imaging was done by keeping the slide within a closed chamber with a constant temperature of 30°C. Images were acquired continuously at 1 frame/2–5 s, depending on the signal intensity, with motorized GFP and CFP filters. To determine the patch lifetime, >30 patches of each protein were visually analyzed for their time courses between patch appearance and disappearance, and the lifetime was calculated as the average time course \pm SD.

RESULTS

Interaction of Scd5p with Pan1p and End3p

To establish the link between Scd5p and Pan1p, we first tested the interaction between the two proteins by yeast two-hybrid assays. As shown in Figure 1A (top right), the N-terminal half of Scd5p displayed a clear interacting activity with the LR2 region of Pan1p. Dissection of SCD5-N into two smaller fragments yielded one with no LR2-binding activity (SCD5-N1) and another with an autoactivity (SCD5-N2). To clarify this issue, we carried out in vitro binding assays using His-tagged Scd5p fragments and GST-LR2. The results showed that SCD5-N2, which contains three Prk1p phosphorylation sites (LxxTxTG), could efficiently pull down GST-LR2 (Figure 1B, lane 6). The interaction between Scd5p and Pan1p was further confirmed by coimmunoprecipitation. Endogenously expressed Scd5-HA could be pulled down by the anti-Myc antibody when Pan1-Myc was coexpressed (Figure 1C, lane 4), indicating that Scd5p interacts with Pan1p in vivo.

Concurrently, we also tested the possibility of an interaction between Scd5p and End3p, which is known to form a complex with Pan1p in vivo (Tang et al., 1997). Two-hybrid assays revealed that SCD5-N could bind to the N terminus of End3p (Figure 1A, bottom right), which is noteworthily not involved in the interaction with Pan1p (Tang *et al.*, 1997). This result was again supported by coimmunoprecipitation experiments (Figure 1D). We could not, however, detect an interaction between Scd5p and Sla1p, another endocytic protein that associates with Pan1p and End3p in vivo (Tang et al., 2000), by the two-hybrid assay (data not shown). In support of the finding that Scd5p interacts with both Pan1p and End3p, a temperature-sensitive mutant of *scd5* defective in endocytosis and actin organization, scd5-1 (Chang et al., 2002; Huang et al., 2003), exhibited synthetic lethality with either *pan1-4* (Tang and Cai, 1996), or *end3* Δ (Figure 1E), indicating that these genes have functions in common. Together, these experiments confirm a physical and functional association between Scd5p and the Pan1p–End3p complex, thus making Scd5p a possible link between Glc7p and Pan1p for the dephosphorylation purpose.

Elevation of Pan1p Phosphorylation Level in scd5 and end3 Mutants

Pan1p is known to be phosphorylated by Prk1p on potentially a large number of threonine residues present as the LxxQxTG motifs and clustered in the LR1 and LR2 regions (Zeng and Cai, 1999). The steady-state phosphorylation level of endogenously expressed Pan1p could be revealed by a phosphothreonine-specific antibody (anti-PThr), as shown in Figure 2A (left, lane 2). As expected, it was drastically reduced in the *prk1* Δ mutant (to ~15% of the wild-type control). In contrast, the Pan1p phosphorylation level was found to be significantly increased in the *scd5-1* mutant at the nonpermissive temperature of 37°C (Figure 2B). This result shows that the phosphorylation status of Pan1p in vivo is dependent on the activity of Scd5p. As the *scd5-1* allele is impaired in binding to Glc7p (Chang *et al.*, 2002;



Figure 1. Interactions of Scd5p with Pan1p and End3p. (A) Two-hybrid interactions of Scd5p with Pan1p and End3p. The regions of Scd5p, Pan1p, and End3p used for two-hybrid assays were schematically shown on left. Domains and motifs important for each protein are also indicated. PBM, phosphatase binding motif; LR, long repeat; EH, Eps15 homology; C.C., coiled-coil; A, acidic motif; P.P., polyproline; PIP₂, phosphatidylinositol 4,5-bisphosphate binding motif; ER, End3 repeat. Two-hybrid interactions were quantified by measuring β -galactosidase activity and expressed in Miller units with SD. Results are the average of three independent transformants. auto, autoactivity; n.d., not determined. (B) In vitro binding assays between Scd5p and Pan1p. Different fragments of His-tagged Scd5p (arrows) were bead immobilized and incubated with GST-LR2 (arrowhead) or GST, respectively. The precipitates, as well as portions of GST and GST-LR2 (loaded on lanes 1-2 as positive controls), were separated by gel electrophoresis and sequentially immunoblotted with anti-GST and anti-His antibodies. A cross-reaction between anti-GST antibody and His-SCD5-C was observed (lanes 7 and 8). (C) Coimmunoprecipitation of Scd5p with Pan1p. Yeast extracts prepared from YMC448 (lanes 1, 5, and 7), YMC441 (lanes 2, 6, and 8), or YMC471 (lanes 3-4 and 9), were subjected to anti-Myc or anti-HA immunoprecipitation followed by gel electrophoresis, and then they were immunoblotted with anti-Myc and anti-HA antibodies, as indicated. (D) Coimmunoprecipitation of Scd5p with End3p. Yeast extracts prepared from YMC448 (lanes 8 and 13), YMC474 containing pMyc-End3-314 (lane 2), YMC474 containing pMyc-End3ΔN-314 (lane 3), YMC474 containing pMyc-End3ΔC-314 (lane 4), YMC476 containing pMyc-End3-314 (lanes 5, 9, and 14), YMC476 containing pMyc-End3ΔN-314 (lanes 6, 10, and 15), and YMC476 containing pMyc-End3ΔC-314 (lanes 7, 11, and 16), were subjected to anti-Myc or anti-HA immunoprecipitation followed by gel electrophoresis, and immunoblotted with anti-Myc and anti-HA antibodies, as indicated. (E) Genetic interactions of Scd5p with Pan1p and End3p. YMC472 transformed with pRS314 or pPAN1-314 (top) and YMC475 transformed with pRS314 or pEND3-314 (bottom) were tested for growth on synthetic complete medium containing 1 mg/ml 5-fluoroorotic acid at 25°C for 5 d.



Figure 2. Phosphorylation level of Pan1p in scd5 and end3 mutants. Endogenously expressed Pan1-Myc was immunoprecipitated from cells and sequentially immunoblotted with anti-PThr and anti-Myc antibodies. (A) Pan1-Myc from YMC441 (lanes 1 and 2) and YMC478 (lane 3) cells at 30°C. The immunoprecipitates in lane 1 were incubated with 1 µl of CIP for 30 min at 37°C before loading. (B) Pan1-Myc from YMC441 (lanes 1 and 3) and YMC479 (lanes 2 and 4) cells at either 25°C (lanes 1 and 2) or 37°C for 3 h (lanes 3 and 4). (C) Pan1-Myc from YMC441 (lanes 1 and 3) and YMC480 (lanes 2 and 4) cells at either 25°C (lanes 1 and 2) or 37°C for 3 h (lanes 3 and 4). (D) Pan1-Myc from YMC480 cells containing pEND3-314 (lane 1), pEND3ΔN-314 (lane 2), or pEND3 Δ C-314 (lane 3) at 30°C. The phosphorylation level of Pan1-Myc in each sample was measured by densitometer (GS800; Bio-Rad, Hercules, CA) and normalized against its protein amount. The relative phosphorylation intensities were calculated and presented as bar graphs (right).

Huang *et al.*, 2003), the elevation of Pan1p phosphorylation level in this mutant is likely resulted from a deficient access of Glc7p to Pan1p.

End3p may also have a crucial role in Pan1p dephosphorylation, because it has a stronger Scd5p-interacting activity than Pan1p in two-hybrid assays (Figure 1A). More importantly, the interaction between End3p and Pan1p has recently been found to be unaffected by the presence of the Prk1 kinase (Toshima et al., 2007). This is consistent with our domain mapping data showing the region of Pan1p involved in binding with End3p to be located immediately after the second EH domain, and hence outside of the Prk1 phosphorylation region (data not shown). End3p, therefore, could be a preferred entry point for Scd5p-Glc7p to gain access to phosphorylated Pan1p. The level of Pan1p phosphorylation in the *end3* Δ mutant was indeed markedly elevated (Figure 2C). However, it remained unclear whether this was due to a loss of access for Scd5p-Glc7p, or an overphosphorylation by Prk1p, as the binding of End3p

could help shield Pan1p from Prk1p phosphorylation (Zeng and Cai, 1999), or both. To answer this question, we examined different truncation mutants of *end3*. End3p interacts with Scd5p and Pan1p through its N- and C-terminal regions respectively, and removal of either will disable its function as a bridging agent between Scd5p and Pan1p, resulting in an increase in the level of Pan1p phosphorylation. This was indeed the case (Figure 2D). Both End3 Δ N and End3 Δ C mutant proteins complemented the temperature sensitivity of the *end3* null mutant (data not shown), as reported previously (Benedetti *et al.*, 1994), indicating that they were expressed functionally in the cells. Since the C-terminal region of End3p was still capable of binding Pan1p (Tang *et al.*, 1997), the role of End3p is probably more in promoting Pan1p dephosphorylation than protecting it from phosphorylation.

Dephosphorylation of Pan1p by Glc7p In Vitro and In Vivo Next, we sought to test whether Glc7p could directly dephosphorylate Pan1p in vitro. To obtain the phosphorylated



Figure 3. Dephosphorylation of Pan1p and Scd5p by Glc7p in vitro and in vivo. (A) In vitro phosphorylation of Pan1p by Prk1p. Purified GST-LR1 was incubated with immunoprecipitated HA-Prk1p (lanes 3 and 4) or HA-Prk1^{D158Y}p (lane 2) in the presence (lanes 2 and 4) or absence (lane 3) of nonradioactive ATP at 25°C for 3 h. The mixture was separated by gel electrophoresis and immunoblotted with anti-PThr and then anti-GST antibodies. (B and F) In vitro dephosphorylation of Pan1p (B) and Scd5p (F) by Glc7p. Immunoprecipitated Glc7-HA with or without the I-2 treatment was incubated with in vitro phosphorylated GST-LR1 or GST-SCD5 at 37°C. Samples were taken at 20-min intervals, electrophoresed, and immunoblotted with anti-PThr and anti-GST antibodies. (C and G) Measurement of Glc7p phosphatase activity on Pan1p (C) and Scd5p (G). The phosphorylation level of GST-LR1 (Figure 3B) and GST-SCD5 (Figure 3F) at each time point was measured by densitometer and normalized against its protein amount. (D) Pan1p phosphorylation level in *glc7-td* mutant. YMC484 (lanes 4-6) and YMC485 (lanes 1-3) cells were allowed to grow to the log phase at 25° C and then shifted to 37° C. Samples were taken at 0, 30, and 60 min, and Pan1p-Myc was immunoprecipitated, electrophoresed, and immunoblotted with anti-PThr and subjected to Western analysis to assay the expression level of Glc7p. (E) Pan1p phosphorylation level in *glc7-T152K* mutant. Pan1-Myc was immunoprecipitated from YMC441 (lane 1) and YMC482 (lanes 2-3) cells grown at 30° C. The immunoprecipitates in lane 3 were preincubated with CIP for 30 min before loading. (H) Phosphorylation of Scd5p

form of Pan1p, GST-LR1, which contains multiple Prk1p phosphorylation sites (Zeng and Cai, 1999), was subjected to phosphorylation by Prk1p in the presence of nonradioactive ATP. As shown in Figure 3A, GST-LR1 could be detected by the anti-PThr antibody after an incubation with immunoprecipitated HA-Prk1p, and no signal was detected if a kinasedead mutant, Prk1^{D158Y}p (Zeng and Cai, 1999), was used. The phosphorylated GST-LR1 thus obtained gradually reduced its phosphorylation level during incubation with immunoprecipitated Glc7-HA to, for example, ~20% after 80 min (Figure 3, B and C). This reduction in GST-LR1 phosphorylation was effectively blocked by I-2 (Figure 3, B and C), a phosphatase inhibitor previously demonstrated to be specific for type 1 protein phosphatases (Cohen et al., 1989). Similar results were also obtained using phosphorylated GST-LR2 as the substrate in the assay (data not shown). These experiments confirmed that Glc7p could execute dephosphorylation of Pan1p in vitro.

We further examined the effect of Glc7p on the phosphorylation level of Pan1p in vivo. To create a conditional mutant of Glc7p, a GLC7 construct containing a heat-inducible degradation signal fused to the N terminus (He and Moore, 2005), along with an HA epitope, was obtained and used to replace the wild type locus in our test strain. The mutant thus created, glc7-td, displayed a temperature-dependent decline in the amount of Glc7p protein (Figure 3D). The depletion of Glc7p was not observed if the degradation signal in the mutant was disrupted (Figure 3D, glc7-ntd). It is evident that the phosphorylation level of Pan1p in glc7-td cells increased in accordance with the depletion of Glc7p, while remained unchanged if Glc7p was not degraded (Figure 3D and Supplemental Figure S1A). Moreover, another mutant, glc7-T152K, previously characterized to be defective in association with Scd5p (Tu et al., 1996), also exhibited an elevated level of Pan1p phosphorylation (Figure 3E and Supplemental Figure S1B). These results allowed us to conclude that Glc7p, through its binding to Scd5p, is required for dephosphorylation of Pan1p in vivo.

Dephosphorylation of Scd5p by Glc7p In Vitro and In Vivo

Similar to Pan1p, Scd5p is also phosphorylated by Prk1p, and the phosphorylation sites are adjacent to the Glc7p binding motif (Henry *et al.*, 2003; Huang *et al.*, 2003). Therefore, Scd5p may also undergo dephosphorylation by Glc7p. To evaluate the effect of Glc7p on the phosphorylation status of Scd5p, we applied the similar assays as described above to Scd5p. First, purified GST-SCD5 was made suitable for in vitro phosphatase assay by incubation with nonradioactive ATP and Prk1p, and the resultant phosphorylated GST-SCD5 was assayed with immunoprecipitated Glc7-HA. As shown in Figure 3, Glc7p could efficiently dephosphorylate GST-SCD5 in vitro, and again, a preincubation with I-2 completely inhibited the Glc7p activity (Figure 3, F and G). Next, the phosphorylation status of Scd5p in vivo was analyzed. The steady-state phosphorylation level of Scd5p in wild-type cells turned out to be below detection, owing likely to the complex formation with Glc7p in vivo (Chang et al., 2002). It was possible to increase the basal phosphorylation level of Scd5p by adding phosphatase inhibitors to the culture medium (Figure 3H). Deletion of PRK1 reduced Scd5p phosphorylation to 36% of the wild-type level under the same condition, whereas disruption of Prk1p phosphorvlation sites (SCD5^{AAA}) extinguished the signal (Figure 3H and Supplemental S1C), indicating that Scd5p was phosphorylated mainly by Prk1p, although other Prk1p-like kinases (Ark1p or Akl1p) could also phosphorylate Scd5p in the absence of Prk1p (Henry et al., 2003). Similarly to Pan1p, the level of phosphorylated Scd5p was substantially increased in the glc7-td mutant after the phosphatase was depleted by temperature shift (Figure 3I and Supplemental Figure S1D). Moreover, the increase in the Scd5p phosphorylation level was also observed in cells containing either the T152K mutation on Glc7p or PBM2 Δ on Scd5p (Figure 3J and Supplemntal S1E), both of which are known to impair the interaction between Glc7p and Scd5p (Tu et al., 1996; Chang et al., 2002; Huang et al., 2003). These results demonstrated that the activity of Glc7p and its interaction with Scd5p are required for maintaining Scd5p in an un- or underphosphorylated state in vivo.

Partial Suppression of glc7-td by prk1 Δ

The involvement of Glc7p in dephosphorylation of Pan1p and Scd5p in vivo suggests that it plays an antagonistic role to the Prk1p kinase in the regulation of actin and endocytosis. To investigate the functional relationship between the phosphatase and the kinase, we examined the actin cytoskeleton organization in the respective mutants. As shown in Figure 4A, the *glc7-td* mutant exhibited a grossly distorted actin cytoskeleton after a prolonged incubation at 37°C (6 h) to diminish the Glc7p protein content (Figure 4A, center). The majority of glc7-td cells contained large and aberrant actin aggregates similar to those found in the pan1-4, scd5-1, and $end_{3\Delta}$ mutants (Benedetti *et al.*, 1994; Tang and Cai, 1996; Huang et al., 2003). In contrast, the control cells (glc7ntd) maintained a normal pattern of actin cytoskeleton after the same treatment (Figure 4A, top), suggesting that the actin abnormalities in glc7-td cells were caused by the phosphatase depletion. Remarkably, the actin defects in glc7-td cells could be largely reversed by deletion of PRK1, because the *prk1* Δ *glc7-td* cells generally showed normal-looking cortical patches, although some aberrant actin aggregates were still visible in a minority of the double mutant cells (Figure 4A, bottom). This result is consistent with the proposed functional antagonism between Glc7p and Prk1p in the regulation of actin cytoskeleton organization.

To see whether depletion of Glc7p also results in an endocytic defect, we carried out the uracil permease internalization assay, by which the endocytic defect could be measured quantitatively. The yeast uracil permease is a plasma membrane protein that is internalized for degradation via the endocytic pathway (Volland *et al.*, 1994). As shown in Figure 4B, after 6 h of incubation at 37°C, the control cells of *glc7-ntd* internalized uracil permease normally and exhibited a rapid decrease in uracil uptake upon addition of

Figure 3 (cont). in vivo. YMC448 (lanes 1-2), YMC449 (lane 3), and YMC488 (lane 4) cells expressing either Scd5-HA (lanes 1 and 2 and 4) or Scd5^{AAA}-HA (lane 3) were grown at 30°C and incubated with phosphatase inhibitor cocktail for 2 h. The HA-tagged proteins were immunoprecipitated, electrophoresed, immunoblotted with anti-PThr and then anti-HA antibodies. (I) Scd5p phosphorylation level in glc7-td mutant. Log phase YMC492 (lanes 1 and 2) and YMC493 (lanes 3 and 4) cells at 25°C were incubated with phosphatase inhibitor cocktail for 2 h and shifted to 37°C. Samples were taken at 0 and 60 min, and Scd5-Myc was immunoprecipitated, electrophoresed, and immunoblotted with anti-PThr and then anti-Myc antibodies. The expression level of Glc7p in each time point was also assayed by Western analysis. (J) Scd5p phosphorylation level in cells containing either T152K mutation on Glc7p or PBM2Δ mutation on Scd5p. Log phase YMC487 (lanes 1 and 3), YMC490 (lane 4), and YMC489 (lane 2) cells at 25°C were shifted to 37°C for 4 h with phosphatase inhibitor cocktail present during the last 2 h. The HA-tagged proteins were immunoprecipitated, electrophoresed, and immunoblotted with anti-PThr and then anti-HA antibodies.



Figure 4. Suppression of *glc7-td* by *prk1*Δ. (A) Actin staining of *glc7-ntd* (YMC499), *glc7-td* (YMC500), and *prk1*Δ *glc7-td* (YMC501) cells. The strains were grown at 25°C to early log phase and incubated at 37°C for 6 h followed by fixation and staining with rho damine-phalloidin. Bar, 4 μ m. (B) Uracil permease internalization assay of *glc7-ntd*, *glc7-td*, *prk1*Δ *glc7-td*, and *scd5-1* cells. The cells were transformed with pFUR4-424, and the transformants were grown at 25°C to OD₆₀₀ of 0.2–0.3. After incubated at 37°C for 6 h, cultures were brought back to 25°C, and the internalization of uracil permease was initiated by the addition of cycloheximide (CHX). Transport of [³H]uracil into yeast cells was used as a measurement for the relative amount of uracil permease retained on the cell surface. Uracil uptake is plotted as the percentage activity relative to the initial time point. The results shown are the averages of two independent assays. (C) The growth of *glc7-ntd*, *glc7-td*, and *prk1*Δ

cycloheximide to suppress protein synthesis. In contrast, the scd5-1 cells, whose severe endocytic defects had been reported before (Huang et al., 2003), maintained a high activity of uracil uptake. Under the same condition, the *glc7-td* cells showed a mildly but consistently slower decline in uracil uptake activity, indicating that the internalization of uracil permease was somewhat impaired in these cells (Figure 4B). The mild retardation in the loss of uracil uptake activity of the *glc7-td* cells was clearly attributable to the diminished phosphatase activity, because it could be corrected by removal of the Prk1p kinase. The *prk1* Δ *glc7-td* double mutant cells internalized uracil permease as efficiently as glc7-ntd cells (Figure 4B). The mild rather than severe defect in endocytosis in the glc7-td cells, as opposed to the actin defects described above, is likely due to the fact that the depletion of the phosphatase under these conditions was hardly complete, and the residual amount of Glc7p remained detectable even after 6 h of incubation at 37°C (data not shown). These observations suggest that the aspect of function of the Pan1p-associated complex with respect to actin is more sensitive to the Prk1p phosphorylation than that with respect to endocytosis.

Furthermore, we found that the growth defect of *glc7-td* mutant could also be partially suppressed by *prk1* Δ . As shown in Figure 4C, the *glc7-td* cells grew well at 25°C but could not sustain the growth at either 33 or 37°C. Deletion of the *PRK1* gene rendered the *glc7-td* cells capable of much better growth at these temperatures, even though they were eventually still inviable (Figure 4C). This partial suppression of *glc7-td* by *prk1* Δ was not due to any recovery of the Glc7p protein level, because the level of the phosphatase remained same in both *glc7-td* and *prk1* Δ *glc7-td* cells at 25°C, and it was diminished at a similar rate at 33 and 37°C (Figure 4D).

Regulation of Scd5p-dependent Interactions by Prk1p Phosphorylation

To gain more insight into the mechanism of dephosphorylation of Pan1p by Glc7p, we examined the interactions among Scd5p, Pan1p, End3p, and Glc7p in more detail. The conspicuously low in vivo phosphorylation level of Scd5p led us to consider the prospect that Scd5p must be present in an unphosphorylated form to fulfill its role as a phosphatase-targeting factor. It is worth noting that both Pan1p and End3p bind to the region of Scd5p where the three Prk1p phosphorylation sites are located (Figure 1). Prk1p phosphorylation has been shown to disfavor the multivalent interaction between Pan1p and other proteins (Zeng et al., 2001; Toshima et al., 2005). It is therefore important to find out whether the interactions of Scd5p with Pan1p, End3p, and Glc7p could be affected by Prk1p phosphorylation on Scd5p. Mutations were generated at the Prk1p phosphorylation sites of Scd5p to convert the three T residues into either A or E to mimic unphosphorylated and phosphorylated states of Scd5p, respectively. Two-hybrid assays revealed that these mutations affected the interactions of Scd5p with both Pan1p and End3p, but not with Glc7p (Figure 5, A-C). Compared with the wild-type, Scd5AAAp

glc7-td strains at different temperatures. Cells were grown at 25°C to OD₆₀₀ of 0.5, and 10× serial dilutions of each culture were dropped onto CuSO₄-containing plates for incubation at the indicated temperatures for 2 d. (D) Comparison of the Glc7p protein level in *glc7-td*, and *prk1*Δ *glc7-td* strains. Cells were grown at 25°C to log phase and then shifted to either 33°C or 37°C for 1 h. Samples were taken at 0 and 60 min. Total proteins of each sample were prepared and subjected to Western analysis.



Figure 5. Phosphoregulation of Scd5p-related interactions. (A–C) Two-hybrid interactions of wild-type (SCD5), SCD5^{AAA}, and SCD5^{EEE} with Pan1p (A), End3p (B), and Glc7p (C). (D) In vitro binding assays between Scd5p and phosphorylated Pan1p. His-tagged SCD5-N2 was immobilized and incubated with unphosphorylated GST-LR2 (lane 3) and phosphorylated GST-LR2P (lane 4), respectively. The precipitates, together with portions of GST-LR2 and GST-LR2P (lane 1–2), were separated by gel electrophoresis and sequentially immunoblotted with anti-GST and anti-His antibodies. (E) The effect of SCD5^{AAA} mutation on Prk1p-induced Pan1p phosphorylation. YMC471 and YMC473 cells containing pGAL-PRK1-313 were allowed to grow at 30°C to log phase in raffinose, followed by addition of galactose. Samples were taken at the indicated time points. Pan1-Myc was immunoprecipitated, electrophoresed, and immunoblotted with anti-PThr and anti-Myc antibodies. (F) Calculation of the relative phosphorylation intensity of Pan1-Myc in Figure 5E. The phosphorylation level of Pan1-Myc in each lane was measured by densitometer and normalized against its protein amount. The relative phosphorylation intensities of all lanes were calculated against lane 1.

exhibited a stronger binding activity with both Pan1p and End3p (increased to 196% for Pan1p and 125% for End3p), whereas Scd5EEEp showed a considerably reduced binding, to \sim 60%, with the two proteins (Figure 5, A and B). These results are of a good indication that the interactions of Scd5p with Pan1p and End3p are both negatively regulated by phosphorylation on Scd5p. The binding with phosphatase Glc7p, in contrast, remained at a similar level irrespective of mutations (Figure 5C), suggesting that the Scd5p–Glc7p interaction was not affected by Scd5p phosphorylation. We also examined the effect of Pan1p phosphorylation on its interaction with Scd5p using an in vitro binding assay. As shown in Figure 5D, the bead-bound His-SCD5-N2 was able to bind unphosphorylated GST-LR2 efficiently, but failed to do the same to phosphorylated GST-LR2. These results suggest that Scd5p may not be able to target Glc7p to the phosphorylated Pan1p directly. Instead, it may do so via its binding to End3p, whose association with Pan1p in vivo is not affected by phosphorylation of Pan1p (Toshima et al., 2007).

The observation that phosphorylation of Scd5p impairs its interaction with the Pan1p–End3p complex suggests that the

dissociation of Scd5p from Pan1p-End3p is one of the consequences after Prk1p phosphorylation. If this is the case, it will be interesting to find out whether the phosphorylation and dissociation of Scd5p is required for, or independent of, the phosphorylation of Pan1p. To address this question, we overexpressed the PRK1 gene from the GAL1 promoter to enhance the Pan1p phosphorylation in vivo in the nonphosphorylatable scd5^{AAA} mutant. As shown in Figure 5, E and F, the level of Pan1p phosphorylation in the wild-type cells was elevated \sim 3.5-fold after 4 h of kinase overexpression. In contrast, the scd5^{AAA} mutant, whose steady-state Pan1p phosphorylation level was already lower before the induction, only showed a slight increase under the same conditions (Figure 5, E and F). This result suggests that phosphorylation of Pan1p has to be preceded by the phosphorylation of Scd5p in vivo. Scd5p, therefore, may serve as a switch in the event of Pan1p phosphorylation in addition to its role as a phosphatase-targeting factor.

Live Cell Imaging of Pan1p, Scd5p, and Prk1p

To correlate the above-mentioned studies with the patterns of protein localization, we examined the real-time protein dynamics of Pan1p, Scd5p, and Prk1p in live cells. In agreement with previous studies (Kaksonen *et al.*, 2003, 2005; Sun *et al.*, 2006), the Pan1-GFP–labeled cortical patches showed restricted movement and exhibited a patch lifetime of ~28 s (Figure 6, A and B, and Supplemental Movie 1). The Scd5-GFP patches were virtually of the same pattern of dynamics with a life span of ~27 s (Figure 6, A and B, and Supplemental Movie 2). The Prk1-GFP patches, on the other hand, had a shorter lifetime (~17 s) and higher motility (Figure 6, A and B, and Supplemental Movie 3). Two-color imaging revealed that Scd5-GFP was recruited to cortical patches at the same point as Pan1-CFP, and the two proteins colocal-

ized with each other on most of the patches, and disappeared together in the end (Figure 6, C–E, and Supplemental Movie 4). In contrast, Prk1-GFP joined the Pan1-CFP patches at a much later stage, just a few seconds before Pan1-CFP began to fade. It coexisted with Pan1-CFP transiently, and vanished shortly after the disappearance of Pan1-CFP (Figure 6, F–H, and Supplemental Movie 5). These data support the earlier suggestion that the Pan1p and Scd5p are components of the same endocytic complex, and phosphorylation by Prk1p leads to their dissociation. The disappearance of Pan1p and Scd5p from cortical patches shortly after the



Figure 6. Live cell imaging of Pan1p, Scd5p, and Prk1p patches. (A) Single frames from movies of wild-type cells expressing Pan1-GFP (YMC494), Scd5-GFP (YMC496), and Prk1-GFP (YMC495). Movies were taken with the frame intervals of 2 s for Pan1-GFP and Prk1-GFP, and 4 s for Scd5-GFP. See Supplemental Movies S1–S3. (B) Lifetimes \pm SD of Pan1-GFP, Scd5-GFP, and Prk1-GFP patches in wild-type cells. $n \ge 30$ for each protein. (C and F) Single frames from two-color movies of live cells expressing Pan1-CFP and Scd5-GFP (YMC498; C) or Pan1-CFP and Prk1-GFP (YMC497; F). Movies were taken with frame intervals of 5 s for C and 3 s for F. See Supplemental Movies S4 and S5. (D and G) Time series from two-color movies showing the dynamic localization of Scd5-GFP (D) and Prk1-GFP (G) in reference to Pan1-CFP. More than 20 patches were examined in each case, and ~90% of them had similar behaviors as shown. (E and H) Plots of patch fluorescence intensities in Figure 5D (E) and Figure 5G (H) with time. (I) Lifetimes \pm SD of Pan1-GFP patches in YMC494 cells transformed with pRS424, pEND3-424, or pSCD5-424. $n \ge 30$ patches. (J) Lifetime of Pan1-GFP patches in wild-type (YMC494) and scd5^{AAA} mutant (YMC499) cells. $n \ge 30$ patches. All scale bars are 4 μ m.

arrival of Prk1p suggests that these two proteins are diffused into cytosol after they are phosphorylated by Prk1p.

Consistently, overproduction of End3p and Scd5p, both of which caused marked reduction in phosphorylation of Pan1p by Prk1p (data not shown), dramatically prolonged the patch life of Pan1-GFP to 40 and 45 s, respectively (Figure 6I). The life span of Pan1-GFP patches was also significantly extended in the *scd5*^{AAA} mutant (Figure 6J), in agreement with the above-mentioned observation that Pan1p phosphorylation was hindered in this mutant. In summary, the behaviors of the fluorescent Scd5p and Prk1p in live cells correlate very well with their roles in phosphoregulation of Pan1p.

DISCUSSION

Phosphorylation and dephosphorylation are the most commonly occurring scheme of regulation in a wide variety of biological processes. Pathways like endocytosis, which require recurrent assembly and disassembly of multiprotein complexes at restricted cellular locations, are perhaps best suited to this type of regulation. Our current understanding of phosphoregulation of actin-coupled endocytosis in yeast has been limited to some of the actions of the Prk1p family of kinases. In this report, we reveal that the type 1 phosphatase Glc7p also takes part in this regulatory circuit, counteracting Prk1p in modifying the phosphorylation status, and hence the activity, of the important endocytic protein Pan1p.

Glc7p as the Phosphatase for Pan1p Dephosphorylation

Glc7p is an essential type 1 protein phosphatase localized in the nucleus and the cytosol, and known to participate in diverse cellular processes (Stark, 1996). Although it has recently been implicated in the regulation of actin organization and endocytosis by the finding that it interacts with Scd5p (Chang et al., 2002), its exact function in this aspect has remained unexplored. We demonstrated that Glc7p is responsible for modulating the in vivo phosphorylation status of at least two regulatory targets of the Prk1p kinase, i.e., Pan1p and Scd5p, both of which are essential for normal actin organization and endocytosis. The findings that pinpoint Glc7p as the phosphatase to dephosphorylate Pan1p include the phosphorylation level of Pan1p being markedly elevated in Glc7p-depleted cells, the phosphatase being able to dephosphorylate Pan1p in vitro, and the interaction with Scd5p being critical for maintaining the normal steady-state phosphorylation level of Pan1p. Although Glc7p was found to interact with Pan1p directly in a report of a large-scale two-hybrid screen (Uetz et al., 2000), we have failed to confirm such interaction in our assays (data not shown).

The role of Glc7p in dephosphorylation of Pan1p is also supported by the functional antagonism between Glc7p and Prk1p. The defects resulted from phosphatase depletion in *glc7-td* cells including actin aggregation, mild delay in endocytosis of uracil permease, and cell lethality, could all be at least partially alleviated by deletion of the kinase gene. As Glc7p is empowered with multifarious cellular functions, it is expected that removal of just one of its antagonistic kinases with a specialized function in actin and endocytosis will not be able to fully compensate for the loss of the phosphatase activity. Nevertheless, the much improved survival of the *prk1*\Delta *glc7-td* cells at high temperatures does indicate that the actin- and endocytosis-related dephosphorylation is an important part of the overall Glc7p cellular functions.

Glc7p should be the major protein phosphatase for Pan1p dephosphorylation, because the Pan1p phosphorylation

level was not altered in the mutants defective in Ppz1p and Ppz2p (our unpublished data), two other phosphatases that share some overlapping functions with Glc7p (Venturi *et al.*, 2000).

The Roles of Scd5p in Phosphoregulation of Pan1p

The key to the mechanism of Pan1p dephosphorylation by Glc7p is the Glc7p targeting factor Scd5p. On one hand, it links the phosphatase to Pan1p by interacting with both Pan1p and End3p. Our results are consistent with the conclusion that Scd5p is essential for maintaining the physiological phosphorylation level of Pan1p by acting as a phosphatase-targeting factor. Scd5p, on the other hand, may also act as a switch in the phosphoregulation of Pan1p, because the phosphorylation status of Pan1p in vivo is dependent on that of Scd5p. When phosphorylation takes place, Prk1p may be obliged to phosphorylate Scd5p first before it can phosphorylate Pan1p, as suggested from the experiment that the nonphosphorylatable Scd5p (Scd5AAA) blocked phosphorylation of Pan1p by overexpressed Prk1p. This mechanism can be interpreted as to ensure the release of Scd5p from the Pan1p-End3p complex in the event of phosphorylation, as the dissociation of Scd5p from the Pan1p-End3p complex is likely required for its binding with Glc7p in the cytosol. The free and phosphorylated Scd5p, in effect, serves as a feedback signal for the process of dephosphorylation.

Therefore, the role of Scd5p in the phosphoregulation of Pan1p during endocytosis is twofold: the patch-localized Scd5p, in complex with Pan1p–End3p, functions as a switch in the event of phosphorylation, whereas the cytoplasmic Scd5p, in complex with Glc7p, acts as a phosphatase targeting factor in the event of dephosphorylation. Of the two roles of Scd5p, only the latter is essential. It has been reported that the cortical localization of Scd5p is not required for its actin and endocytic functions, since these functions remained apparently normal in a cytoplasmically localized Scd5p mutant (Chang et al., 2006). This mutant, nevertheless, is expected to be functional as the phosphatase-targeting factor, because it is still able to interact with End3p in the cytosol. The *scd5*- Δ 338 mutant, on the other hand, is temperature sensitive and defective in endocytosis, because the truncated protein is predominantly localized to the nucleus (Henry et al., 2002; Chang et al., 2006). Consistent with our findings, this mutation could be suppressed by deletion of the kinase gene PRK1 (Henry et al., 2003).

Cycle of Phosphoregulation of Pan1p during Endocytosis

With the identification of the role of the Scd5p-Glc7p phosphatase complex in dephosphorylation of Pan1p, combined with previous discoveries made by other groups, it is now possible to propose a model of a complete cycle of the phosphoregulation of Pan1p during endocytosis (Figure 7): 1) Assembly of the endocytic complex at the site of endocytosis, in which Pan1p is complexed with End3p and Scd5p, together with other coat proteins and present in an unphosphorylated state. 2) Initiation of actin polymerization by the Arp2/3p complex to induce membrane invagination. 3) Vesicle scission and inward movement propelled by actin polymerization. 4) Phosphorylation of Scd5p and Pan1p by Prk1p to disassemble the coat complex. Incorporation of the kinase into the complex at this stage involves Abp1p (Fazi et al., 2002), which appears on the Pan1p patches at about same time as Prk1p (Kaksonen et al., 2003). The kinase starts by phosphorylating and dissociating Scd5p from Pan1p and End3p, followed by extensive phosphorylation of Pan1p. This presumably will cause a distortion/disrup-



Figure 7. Simplistic model of actin-driven endocytosis in yeast with an emphasis on phosphoregulation of Pan1p by Prk1p and Glc7p. Steps 1 through 4 occur on the cortical patches, and step 5 (dephosphorylation) takes place in the cytosol. See text for detailed description.

tion of the interactions among endocytic coat proteins and a termination of Pan1p-dependent actin polymerization. 5) Dephosphorylation of Pan1p in the cytosol. Phosphorylated Scd5p is released into cytosol, so is phosphorylated Pan1p, which remains to be bound by End3p (Toshima et al., 2007). Scd5p is then bound and dephosphorylated by Glc7p, whose binding with Scd5p is unaffected by Prk1p phosphorylation. Dephosphorylation of Pan1p starts by reassociation of Scd5p with End3p. Once it initiates, dephosphorylation of Pan1p is expected to be a self-accelerating process, as the first cluster of phosphor residues to be cleared are likely those located adjacent to the End3pand Scd5p-binding region (LR2), and dephosphorylation in this region will result in a more secured interaction between Pan1p and Scd5p. This will in turn facilitate the dephosphorylation of other sites located in the LR1 region. Dephosphorylated Pan1p is now once again ready to lead the next round of endocytosis (Figure 7). Glc7p will become detached from the complex probably at the time when dephosphorylated Pan1p and \$cd5p begin to interact with other coat proteins. This model also fits well with our live cell imaging data. For example, we observed that Pan1p and Scd5p have similar patch lifetime, and the two proteins appear on, and disappear from, the patches at about same time. The time of Prk1p arrival on the Pan1p patches is also consistent with the concept that Prk1p phosphorylation initiates disassembly of the endocytic coat complex.

Other Considerations

In addition to Pan1p, other endocytic proteins known to be phosphorylated by Prk1p, such as Sla1p, Ent1/2p and Yap1801/2p (Watson *et al.*, 2001; Zeng *et al.*, 2001; Huang *et al.*, 2003), may also be dephosphorylated by the Scd5p-targeted Glc7p. For example, the yeast homologue of mammalian Huntingtin-interacting protein 1R, Sla2p, which contains a single Prk1p phosphorylation motif (Huang *et al.*, 2003), has been reported to be involved in interactions with Ark1p and Scd5p (Cope *et al.*, 1999; Henry *et al.*, 2002). It will be interesting to find out whether Sla2p is phosphoregulated by Prk1p/Ark1p and Glc7p in a similar manner as Pan1p.

Sla1p has also been reported to interact with Glc7p (Tu *et al.*, 1996; Venturi *et al.*, 2000), although we failed to confirm such interaction in our yeast two-hybrid assays. Whether Sla1p could act as a phosphatase-targeting factor and at the same time a substrate, similarly to Scd5p, remains to be clarified.

In mammalian cells, kinases with similar function and property as that of Prk1p have also been identified. The adaptor-associated kinase AAK1 negatively regulates clathrin-mediated endocytosis by phosphorylating the μ 2 subunit of the AP2 adaptor protein complex (Conner and Schmid, 2002; Ricotta et al., 2002). Interestingly, AAK1 shares with Prk1p not only the extensive kinase sequence homology but also the similar recognition motif (Conner and Schmid, 2002; Ricotta et al., 2002). Another mammalian homologue of Prk1p, GAK, also exhibits a similar specificity on the μ^2 subunit and plays a regulatory role in endocytosis (Zhang et al., 2005). AP2 is known to associate with Eps15, the mammalian counterpart of Pan1p, and such interaction is required for endocytosis (Benmerah et al., 1995, 1998). Unlike Pan1p, however, Eps15 contains no AAK1/GAK recognition motifs, and it has yet to be ascertained whether it is subjected to regulation by these kinases. It also remains unknown how the dephosphorylation of AP2 is carried out. The mammalian PP1 has not been demonstrated to be involved in clathrin-mediated endocytosis, despite its vast variety of other known cellular functions through >50 established or putative binding subunits (Cohen, 2002). Therefore, it will be of great interest to identify novel targeting factor(s) of PP1, or other type of phosphatases, with a specific function in clathrin-mediated endocytosis in mammalian cells.

ACKNOWLEDGMENTS

We are grateful to Claire Moore (Tufts University) for providing the pGLC7degron plasmid (pGLC7n-td-306) and to David Drubin (University of California, Berkeley) for the Pan1-GFP harboring strain DDY3063. We also thank Desmond Dorairajoo and Yong Xiao for helping microscopy and imaging data analysis. We thank Jun Wang and Chong Yun Won for general technical assistance. This work was supported by the Agency for Science, Technology & Research of Singapore. M.C. holds an adjunct faculty appointment from the Department of Biochemistry, Faculty of Medicine, National University of Singapore.

REFERENCES

Benedetti, H., Raths, S., Crausaz, F., and Riezman, H. (1994). The END3 gene encodes a protein that is required for the internalization step of endocytosis and for actin cytoskeleton organization in yeast. Mol. Biol. Cell *5*, 1023–1037.

Benmerah, A., Gagnon, J., Begue, B., Megarbane, B., Dautry-Varsat, A., and Cerf-Bensussan, N. (1995). The tyrosine kinase substrate eps15 is constitutively associated with the plasma membrane adaptor AP-2. J. Cell Biol. *131*, 1831–1838.

Benmerah, A., Lamaze, C., Begue, B., Schmid, S. L., Dautry-Varsat, A., and Cerf-Bensussan, N. (1998). AP-2/Eps15 interaction is required for receptormediated endocytosis. J. Cell Biol. 140, 1055–1062.

Chang, J. S., Henry, K., Geli, M. I., and Lemmon, S. K. (2006). Cortical recruitment and nuclear-cytoplasmic shuttling of Scd5p, a protein phosphatase-1-targeting protein involved in actin organization and endocytosis. Mol. Biol. Cell *17*, 251–262.

Chang, J. S., Henry, K., Wolf, B. L., Geli, M., and Lemmon, S. K. (2002). Protein phosphatase-1 binding to Scd5p is important for regulation of actin organization and endocytosis in yeast. J. Biol. Chem. 277, 48002–48008.

Cohen, P., Klumpp, S., and Schelling, D. L. (1989). An improved procedure for identifying and quantitating protein phosphatases in mammalian tissues. FEBS Lett. 250, 596–600.

Cohen, P. T. (2002). Protein phosphatase 1-targeted in many directions. J. Cell Sci. 115, 241–256.

Conner, S. D., and Schmid, S. L. (2002). Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis. J. Cell Biol. *156*, 921–929.

Cope, M. J., Yang, S., Shang, C., and Drubin, D. G. (1999). Novel protein kinases Ark1p and Prk1p associate with and regulate the cortical actin cy-toskeleton in budding yeast. J. Cell Biol. *144*, 1203–1218.

Dohmen, R. J., Wu, P., and Varshavsky, A. (1994). Heat-inducible degron: a method for constructing temperature-sensitive mutants. Science 263, 1273–1276.

Duncan, M. C., Cope, M. J., Goode, B. L., Wendland, B., and Drubin, D. G. (2001). Yeast Eps15-like endocytic protein, Pan1p, activates the Arp2/3 complex. Nat. Cell Biol. 3, 687–690.

Fazi, B., Cope, M. J., Douangamath, A., Ferracuti, S., Schirwitz, K., Zucconi, A., Drubin, D. G., Wilmanns, M., Cesareni, G., and Castagnoli, L. (2002). Unusual binding properties of the SH3 domain of the yeast actin-binding protein Abp 1, structural and functional analysis. J. Biol. Chem. 277, 5290–5298.

Feng, Z. H., Wilson, S. E., Peng, Z. Y., Schlender, K. K., Reimann, E. M., and Trumbly, R. J. (1991). The yeast GLC7 gene required for glycogen accumulation encodes a type 1 protein phosphatase. J. Biol. Chem. 266, 23796–23801.

Francisco, L., Wang, W., and Chan, C. S. (1994). Type 1 protein phosphatase acts in opposition to IpL1 protein kinase in regulating yeast chromosome segregation. Mol. Cell. Biol. 14, 4731–4740.

He, X., and Moore, C. (2005). Regulation of yeast mRNA 3' end processing by phosphorylation. Mol. Cell 19, 619–629.

Henry, K. R., D'Hondt, K., Chang, J., Newpher, T., Huang, K., Hudson, R. T., Riezman, H., and Lemmon, S. K. (2002). Scd5p and clathrin function are important for cortical actin organization, endocytosis, and localization of sla2p in yeast. Mol. Biol. Cell 13, 2607–2625.

Henry, K. R., D'Hondt, K., Chang, J. S., Nix, D. A., Cope, M. J., Chan, C. S., Drubin, D. G., and Lemmon, S. K. (2003). The actin-regulating kinase Prk1p negatively regulates Scd5p, a suppressor of clathrin deficiency, in actin organization and endocytosis. Curr. Biol. *13*, 1564–1569.

Hisamoto, N., Sugimoto, K., and Matsumoto, K. (1994). The Glc7 type 1 protein phosphatase of *Saccharomyces cerevisiae* is required for cell cycle progression in G2/M. Mol. Cell. Biol. *14*, 3158–3165.

Huang, B., Zeng, G., Ng, A. Y., and Cai, M. (2003). Identification of novel recognition motifs and regulatory targets for the yeast actin-regulating kinase Prk1p. Mol. Biol. Cell *14*, 4871–4884.

Kaksonen, M., Sun, Y., and Drubin, D. G. (2003). A pathway for association of receptors, adaptors, and actin during endocytic internalization. Cell *115*, 475–487.

Kaksonen, M., Toret, C. P., and Drubin, D. G. (2005). A modular design for the clathrin- and actin-mediated endocytosis machinery. Cell *123*, 305–320.

Kaksonen, M., Toret, C. P., and Drubin, D. G. (2006). Harnessing actin dynamics for clathrin-mediated endocytosis. Nat. Rev. Mol. Cell Biol. 7, 404– 414.

Merrifield, C. J. (2004). Seeing is believing: imaging actin dynamics at single sites of endocytosis. Trends Cell Biol. 14, 352–358.

Ricotta, D., Conner, S. D., Schmid, S. L., von Figura, K., and Honing, S. (2002). Phosphorylation of the AP2 mu subunit by AAK1 mediates high affinity binding to membrane protein sorting signals. J. Cell Biol. *156*, 791–795.

Stark, M. J. (1996). Yeast protein serine/threonine phosphatases: multiple roles and diverse regulation. Yeast 12, 1647–1675.

Sun, Y., Martin, A. C., and Drubin, D. G. (2006). Endocytic internalization in budding yeast requires coordinated actin nucleation and myosin motor activity. Dev. Cell *11*, 33–46.

Tang, H. Y., and Cai, M. (1996). The EH-domain-containing protein Pan1 is required for normal organization of the actin cytoskeleton in *Saccharomyces cerevisiae*. Mol. Cell. Biol. *16*, 4897–4914.

Tang, H. Y., Munn, A., and Cai, M. (1997). EH domain proteins Pan1p and End3p are components of a complex that plays a dual role in organization of the cortical actin cytoskeleton and endocytosis in *Saccharomyces cerevisiae*. Mol. Cell. Biol. *17*, 4294–4304.

Tang, H. Y., Xu, J., and Cai, M. (2000). Pan1p, End3p, and S1a1p, three yeast proteins required for normal cortical actin cytoskeleton organization, associate with each other and play essential roles in cell wall morphogenesis. Mol. Cell. Biol. 20, 12–25.

Toshima, J., Toshima, J. Y., Duncan, M. C., Cope, M. J., Sun, Y., Martin, A. C., Anderson, S., Yates, J. R., 3rd, Mizuno, K., and Drubin, D. G. (2007). Negative regulation of yeast Eps15-like Arp2/3 complex activator, Pan1p, by the Hip1R-related protein, Sla2p, during endocytosis. Mol. Biol. Cell 18, 658–668.

Toshima, J., Toshima, J. Y., Martin, A. C., and Drubin, D. G. (2005). Phosphoregulation of Arp2/3-dependent actin assembly during receptor-mediated endocytosis. Nat. Cell Biol. 7, 246–254.

Tu, J., and Carlson, M. (1994). The GLC7 type 1 protein phosphatase is required for glucose repression in *Saccharomyces cerevisiae*. Mol. Cell. Biol. 14, 6789–6796.

Tu, J., and Carlson, M. (1995). REG1 binds to protein phosphatase type 1 and regulates glucose repression in *Saccharomyces cerevisiae*. EMBO J. 14, 5939–5946.

Tu, J., Song, W., and Carlson, M. (1996). Protein phosphatase type 1 interacts with proteins required for meiosis and other cellular processes in *Saccharomyces cerevisiae*. Mol. Cell. Biol. *16*, 4199–4206.

Uetz, P. et al. (2000). A comprehensive analysis of protein-protein interactions in *Saccharomyces cerevisiae*. Nature 403, 623–627.

Venturi, G. M., Bloecher, A., Williams-Hart, T., and Tatchell, K. (2000). Genetic interactions between GLC7, PPZ1 and PPZ2 in saccharomyces cerevisiae. Genetics *155*, 69–83.

Volland, C., Urban-Grimal, D., Geraud, G., and Haguenauer-Tsapis, R. (1994). Endocytosis and degradation of the yeast uracil permease under adverse conditions. J. Biol. Chem. 269, 9833–9841.

Wach, A., Brachat, A., Alberti-Segui, C., Rebischung, C., and Philippsen, P. (1997). Heterologous HIS3 marker and GFP reporter modules for PCR-targeting in *Saccharomyces cerevisiae*. Yeast 13, 1065–1075.

Watson, H. A., Cope, M. J., Groen, A. C., Drubin, D. G., and Wendland, B. (2001). In vivo role for actin-regulating kinases in endocytosis and yeast epsin phosphorylation. Mol. Biol. Cell *12*, 3668–3679.

Wek, R. C., Cannon, J. F., Dever, T. E., and Hinnebusch, A. G. (1992). Truncated protein phosphatase GLC7 restores translational activation of GCN4 expression in yeast mutants defective for the eIF-2 alpha kinase GCN2. Mol. Cell. Biol. *12*, 5700–5710.

Wendland, B., and Emr, S. D. (1998). Pan1p, yeast eps15, functions as a multivalent adaptor that coordinates protein-protein interactions essential for endocytosis. J. Cell Biol. 141, 71–84.

Wendland, B., Steece, K. E., and Emr, S. D. (1999). Yeast epsins contain an essential N-terminal ENTH domain, bind clathrin and are required for endocytosis. EMBO J 18, 4383–4393.

Zeng, G., and Cai, M. (1999). Regulation of the actin cytoskeleton organization in yeast by a novel serine/threonine kinase Prk1p. J. Cell Biol. 144, 71–82.

Zeng, G., Yu, X., and Cai, M. (2001). Regulation of yeast actin cytoskeletonregulatory complex Pan1p/Sla1p/End3p by serine/threonine kinase Prk1p. Mol. Biol. Cell *12*, 3759–3772.

Zhang, C. X., Engqvist-Goldstein, A. E., Carreno, S., Owen, D. J., Smythe, E., and Drubin, D. G. (2005). Multiple roles for cyclin G-associated kinase in clathrin-mediated sorting events. Traffic 6, 1103–1113.